<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Nutr</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Nutr</journal-id><journal-id journal-id-type="publisher-id">BJN</journal-id><journal-title-group><journal-title>The British Journal of Nutrition</journal-title></journal-title-group><issn pub-type="ppub">0007-1145</issn><issn pub-type="epub">1475-2662</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27719686</article-id><article-id pub-id-type="pmc">5082288</article-id><article-id pub-id-type="doi">10.1017/S0007114516003354</article-id><article-id pub-id-type="pii">S0007114516003354</article-id><article-id pub-id-type="publisher-id">00335</article-id><article-categories><subj-group subj-group-type="heading"><subject>Full Papers</subject></subj-group><subj-group subj-group-type="section"><subject>Human and Clinical Nutrition</subject></subj-group></article-categories><title-group><article-title>Oral supplementation of healthy adults with
2&#x02032;-<italic>O</italic>-fucosyllactose and lacto-<italic>N</italic>-neotetraose is well
tolerated and shifts the intestinal microbiota</article-title><alt-title alt-title-type="left-running">E. Elison <italic>et al</italic>.</alt-title><alt-title alt-title-type="right-running">2&#x02032;-<italic>O</italic>-fucosyllactose and
lacto-<italic>N</italic>-neotetraose safely shift adult microbiota</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Elison</surname><given-names>Emma</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Vigsnaes</surname><given-names>Louise K.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rindom Krogsgaard</surname><given-names>Laura</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Rasmussen</surname><given-names>Julie</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>S&#x000f8;rensen</surname><given-names>Nikolaj</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>McConnell</surname><given-names>Bruce</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hennet</surname><given-names>Thierry</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Sommer</surname><given-names>Morten O. A.</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Bytzer</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Glycom A/S</addr-line>, <addr-line>Diplomvej 373</addr-line>, <addr-line>DK-2800
Kgs. Lyngby</addr-line>, <country>Denmark</country></aff><aff id="aff2"><label>2</label><addr-line>Department of Medicine</addr-line>, <institution>Zealand University
Hospital</institution>, <addr-line>Lykkeb&#x000e6;kvej 1</addr-line>, <addr-line>DK-4600
K&#x000f8;ge</addr-line>, <country>Denmark</country></aff><aff id="aff3"><label>3</label><addr-line>Department of Clinical Medicine</addr-line>, <institution>Copenhagen
University</institution>, <addr-line>DK-2200 Copenhagen</addr-line>,
<country>Denmark</country></aff><aff id="aff4"><label>4</label><institution>Clinical-Microbiomics ApS</institution>, <addr-line>Kogle All&#x000e9; 5</addr-line>,
<addr-line>DK-2970 H&#x000f8;rsholm</addr-line>, <country>Denmark</country></aff><aff id="aff5"><label>5</label><addr-line>Institute of Physiology and Zurich Centre of Integrative Human
Physiology</addr-line>, <institution>University of Zurich</institution>, <addr-line>Zurich
CH-8057</addr-line>, <country>Switzerland</country></aff><aff id="aff6"><label>6</label><addr-line>Novo Nordisk Foundation Center for Biosustainability</addr-line>,
<institution>Technical University of Denmark</institution>, <addr-line>Kogle Alle
6</addr-line>, <addr-line>DK-2970 H&#x000f8;rsholm</addr-line>, <country>Denmark</country></aff><author-notes><corresp id="cor1"><label>*</label><bold>Corresponding author:</bold> E. Elison, email <email>ct@glycom.com</email></corresp></author-notes><pub-date pub-type="epub"><day>10</day><month>10</month><year>2016</year></pub-date><pub-date pub-type="ppub"><day>28</day><month>10</month><year>2016</year></pub-date><volume>116</volume><issue>8</issue><fpage>1356</fpage><lpage>1368</lpage><history><date date-type="received"><day>04</day><month>5</month><year>2016</year></date><date date-type="rev-recd"><day>03</day><month>8</month><year>2016</year></date><date date-type="accepted"><day>22</day><month>8</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; The Authors 2016</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>The Authors</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article, distributed under the terms of the Creative
Commons Attribution licence (<uri xlink:type="simple" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted
re-use, distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0007114516003354a.pdf"/><abstract abstract-type="normal"><p>The gut microbiota has been established as an important player influencing many aspects
of human physiology. Breast milk, the first diet for an infant, contains human milk
oligosaccharides (HMO) that shape the infant&#x02019;s gut microbiota by selectively stimulating
the growth of specific bacteria, especially bifidobacteria. In addition to their
bifidogenic activity, the ability of HMO to modulate immune function and the gut barrier
makes them prime candidates to restore a beneficial microbiota in dysbiotic adults and
provide health benefits. We conducted a parallel, double-blind, randomised,
placebo-controlled, HMO-supplementation study in 100 healthy, adult volunteers, consuming
chemically produced 2&#x02032;-<italic>O</italic>-fucosyllactose (2&#x02032;FL) and/or
lacto-<italic>N</italic>-neotetraose (LNnT) at various daily doses and mixes or placebo
for 2 weeks. All participants completed the study without premature discontinuation.
Supplementation of 2&#x02032;FL and LNnT at daily doses up to 20 g was shown to be safe and well
tolerated, as assessed using the gastrointestinal symptoms rating scale. 16S rRNA
sequencing analysis showed that HMO supplementation specifically modified the adult gut
microbiota with the primary impact being substantial increases in relative abundance of
Actinobacteria and <italic>Bifidobacterium</italic> in particular and a reduction in
relative abundance of Firmicutes and Proteobacteria. This study provides the first set of
data on safety, tolerance and impact of HMO on the adult gut microbiota. Collectively, the
results from this study show that supplementing the diet with HMO is a valuable strategy
to shape the human gut microbiota and specifically promote the growth of beneficial
bifidobacteria.</p></abstract><kwd-group><title>Key words</title><kwd>2&#x02032;-<italic>O</italic>-Fucosyllactose</kwd><kwd>Lacto-<italic>N</italic>-neotetraose</kwd><kwd>Clinical study</kwd><kwd>Safety</kwd><kwd>Tolerance</kwd></kwd-group><kwd-group kwd-group-type="abbreviations"><title>Abbreviations</title><compound-kwd><compound-kwd-part content-type="abbrev">2&#x02032;FL</compound-kwd-part><compound-kwd-part content-type="expansion">2&#x02032;-<italic>O</italic>-fucosyllactose</compound-kwd-part></compound-kwd><compound-kwd><compound-kwd-part content-type="abbrev">GI</compound-kwd-part><compound-kwd-part content-type="expansion">gastrointestinal</compound-kwd-part></compound-kwd><compound-kwd><compound-kwd-part content-type="abbrev">GSRS</compound-kwd-part><compound-kwd-part content-type="expansion">gastrointestinal symptom rating
scale</compound-kwd-part></compound-kwd><compound-kwd><compound-kwd-part content-type="abbrev">HMO</compound-kwd-part><compound-kwd-part content-type="expansion">human milk oligosaccharide</compound-kwd-part></compound-kwd><compound-kwd><compound-kwd-part content-type="abbrev">LNnT</compound-kwd-part><compound-kwd-part content-type="expansion">lacto-<italic>N</italic>-neotetraose</compound-kwd-part></compound-kwd><compound-kwd><compound-kwd-part content-type="abbrev">OTU</compound-kwd-part><compound-kwd-part content-type="expansion">operational taxonomic
units</compound-kwd-part></compound-kwd></kwd-group><counts><fig-count count="8"/><table-count count="2"/><page-count count="13"/></counts></article-meta></front><body><p>Intensive research over the past decade has revealed the gut microbiota to be an important
player in host health by influencing many aspects of human physiology, including energy
metabolism<sup>(</sup>
<xref rid="ref1" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>)</sup>, hormonal balance<sup>(</sup>
<xref rid="ref2" ref-type="bibr">
<sup>2</sup>
</xref>
<sup>)</sup> and immunity<sup>(</sup>
<xref rid="ref3" ref-type="bibr">
<sup>3</sup>
</xref>
<sup>,</sup>
<xref rid="ref4" ref-type="bibr">
<sup>4</sup>
</xref>
<sup>)</sup>. The gut microbiota also contributes to establishment of the mucosal barrier and
maintenance of intestinal homoeostasis<sup>(</sup>
<xref rid="ref5" ref-type="bibr">
<sup>5</sup>
</xref>
<sup>)</sup>. The microbiota of the human intestine is a complex and very dynamic microbial
ecosystem, and extensive research has been able to link imbalance in the intestinal bacterial
population to a wide variety of both intestinal and extra-intestinal diseases such as
malnutrition, cancer, inflammatory diseases, metabolic diseases, gastrointestinal (GI)
diseases and response to pathogens<sup>(</sup>
<xref rid="ref6" ref-type="bibr">
<sup>6</sup>
</xref>
<sup>&#x02013;</sup>
<xref rid="ref14" ref-type="bibr">
<sup>14</sup>
</xref>
<sup>)</sup>. This research has led to an increasing appreciation of the gut microbiota as a
target for therapeutic intervention. Indeed, modulation of the gut microbiota has been shown
to be a promising therapeutic approach to treat recurrent <italic>Clostridium
difficile</italic> infections<sup>(</sup>
<xref rid="ref15" ref-type="bibr">
<sup>15</sup>
</xref>
<sup>)</sup>.</p><p>Breast milk, the first diet for an infant, offers all the essential nutrients for growth and
development, and provides bioactive factors such as Ig, antimicrobial proteins and
cytokines<sup>(</sup>
<xref rid="ref16" ref-type="bibr">
<sup>16</sup>
</xref>
<sup>)</sup>. In addition, components of breast milk are able to shape the intestinal
microbiota and drive the maturation of the infant gut. The major components driving this are
the human milk oligosaccharides (HMO), as can be seen when comparing breast-fed with
formula-fed infants, where breast-fed infants carry a more stable and uniform microbial
population than formula-fed infants<sup>(</sup>
<xref rid="ref17" ref-type="bibr">
<sup>17</sup>
</xref>
<sup>)</sup>. HMO are a family of highly diverse structures of unconjugated glycans, present
in high concentrations in human milk. The structural diversity they represent can be broadly
divided into fucosylated, sialylated and non-fucosylated neutral structures. One litre of
mother&#x02019;s milk contains 5&#x02013;25 g of HMO<sup>(</sup>
<xref rid="ref18" ref-type="bibr">
<sup>18</sup>
</xref>
<sup>)</sup>, and HMO therefore are the third most abundant solid constituent in human milk.
HMO are not digested in the upper GI tract, and only 1&#x02013;2 % is absorbed in infants<sup>(</sup>
<xref rid="ref19" ref-type="bibr">
<sup>19</sup>
</xref>
<sup>,</sup>
<xref rid="ref20" ref-type="bibr">
<sup>20</sup>
</xref>
<sup>)</sup>. The majority of ingested HMO reach the large intestine where they provide
selective substrates for specific gut bacteria<sup>(</sup>
<xref rid="ref21" ref-type="bibr">
<sup>21</sup>
</xref>
<sup>&#x02013;</sup>
<xref rid="ref27" ref-type="bibr">
<sup>27</sup>
</xref>
<sup>)</sup>, modulate the immune system<sup>(</sup>
<xref rid="ref28" ref-type="bibr">
<sup>28</sup>
</xref>
<sup>&#x02013;</sup>
<xref rid="ref31" ref-type="bibr">
<sup>31</sup>
</xref>
<sup>)</sup> and prevent the epithelial adhesion of intestinal pathogens<sup>(</sup>
<xref rid="ref32" ref-type="bibr">
<sup>32</sup>
</xref>
<sup>&#x02013;</sup>
<xref rid="ref36" ref-type="bibr">
<sup>36</sup>
</xref>
<sup>)</sup>.</p><p>After weaning, the introduction of solid food profoundly influences the microbial ecology. In
fact, diet is, together with genetics and environmental factors, one of the main contributors
to the diversity of human intestinal microbiota<sup>(</sup>
<xref rid="ref37" ref-type="bibr">
<sup>37</sup>
</xref>
<sup>)</sup>. Dietary manipulation hence represents a strategy to promote a beneficial GI
microbial community and to improve the well-being of the host.</p><p>Selective stimulation of beneficial intestinal bacteria by promoting their growth and
metabolic activity may be a helpful approach in creating a beneficial microbial community. As
some bacteria are able to produce a large set of carbohydrate active enzymes, including
glycoside-hydrolases and transporters, they can grow on carbon sources, which are unfermented
by other members of the intestinal microbial community. HMO are probably best known for their
prebiotic effects in breast-fed infants, where they exert a strong bifidogenic effect,
characterised by the proliferation of specific strains including <italic>Bifidobacterium
infantis</italic>, <italic>B. breve</italic> and <italic>B. bifidum</italic>
<sup>(</sup>
<xref rid="ref17" ref-type="bibr">
<sup>17</sup>
</xref>
<sup>,</sup>
<xref rid="ref38" ref-type="bibr">
<sup>38</sup>
</xref>
<sup>)</sup>. Bifidobacteria are generally considered beneficial for human health because of
their ability to digest complex carbohydrates and dietary fibres. Further, low bifidobacteria
abundance has been linked to GI<sup>(</sup>
<xref rid="ref39" ref-type="bibr">
<sup>39</sup>
</xref>
<sup>,</sup>
<xref rid="ref40" ref-type="bibr">
<sup>40</sup>
</xref>
<sup>)</sup> and metabolic diseases<sup>(</sup>
<xref rid="ref41" ref-type="bibr">
<sup>41</sup>
</xref>
<sup>,</sup>
<xref rid="ref42" ref-type="bibr">
<sup>42</sup>
</xref>
<sup>)</sup>, for example. As <italic>Bifidobacterium</italic> is highly abundant in the
microbiota of breast-fed infants, their acquisition and HMO metabolism have drawn a lot of
attention in recent years<sup>(</sup>
<xref rid="ref43" ref-type="bibr">
<sup>43</sup>
</xref>
<sup>)</sup>. <italic>In vitro</italic> fermentation studies have clearly confirmed the
decisive role of HMO in promoting the growth of bifidobacteria<sup>(</sup>
<xref rid="ref25" ref-type="bibr">
<sup>25</sup>
</xref>
<sup>)</sup>. However, the impact of HMO on the adult intestinal microbiota and adult GI tract
is unknown. We designed a prospective study to assess the effects of HMO supplementation on
the composition of the adult gut microbiota and on GI symptoms. We selected
2&#x02032;-<italic>O</italic>-fucosyllactose (2&#x02032;FL) as a fucosylated HMO and
lacto-<italic>N</italic>-neotetraose (LNnT) as a non-fucosylated neutral HMO. These two
compounds are among the shortest HMO to remain unaltered after passage through the small
intestine and are available for clinical use. This first human study of HMO supplementation in
adults provided valuable insights into the effect of HMO on the adult gut microbiota. In
addition, the study assessed the safety and tolerability of HMO supplementation in adults.</p><sec sec-type="methods" id="sec1"><title>Methods</title><sec id="sec1-1" sec-type="subjects"><title>Subjects</title><p>Subjects were recruited from the region Zealand in Denmark. In total, 110 healthy male
and female adult volunteers were invited for screening. From this pool of volunteers, 100
subjects were randomised to participate in the study. Inclusion criteria were as follows:
aged between 18 and 60 years, ability and willingness to understand and comply with the
study procedures and sign the written informed consent. Exclusion criteria were as
follows: participation in a clinical study 1 month before the screening visit and
throughout the study, abnormal results of screening laboratory and clinical tests relevant
for study participation, any GI symptom scoring &#x0003e;3 on the Gastrointestinal Symptom
Rating Scale (GSRS), a mean score on the total GSRS&#x0003e;2 during the screening period,
any GI and/or other severe diseases, highly dosed probiotic supplement and/or antibiotic
use 3 months before the study and throughout the study, consumption on a regular basis of
medication that might interfere with symptom evaluation, pregnancy or seeking pregnancy
and nursing. A summary of the trial design was registered at <uri xlink:type="simple" xlink:href="http://www.ClinicalTrials.gov">www.ClinicalTrials.gov</uri> (NCT01927900).</p></sec><sec id="sec1-2" sec-type="general"><title>Study products</title><p>All carbohydrate compounds were provided as powder in PET bottles. HMO 2&#x02032;FL and LNnT were
supplied by Glycom A/S as white, free-flowing, crystalline powders of synthetic origin at
99&#x000b7;9 % (2&#x02032;FL) and 98&#x000b7;9 % (LNnT) purity, respectively. The samples were subjected to
preclinical toxicology studies<sup>(</sup>
<xref rid="ref44" ref-type="bibr">
<sup>44</sup>
</xref>
<sup>,</sup>
<xref rid="ref45" ref-type="bibr">
<sup>45</sup>
</xref>
<sup>)</sup>. Furthermore, an European Food Safety Authority (EFSA) panel on Dietetic
Products, Nutrition and Allergies (NDA) specifically assessed 2&#x02032;FL and LNnT and concluded
that these, as produced by Glycom A/S, are safe to use in foods<sup>(</sup>
<xref rid="ref46" ref-type="bibr">
<sup>46</sup>
</xref>
<sup>,</sup>
<xref rid="ref47" ref-type="bibr">
<sup>47</sup>
</xref>
<sup>)</sup>. Glucose (Dextropure; Valora Trade Denmark A/S) was given as placebo.
Subjects were asked to dissolve the contents of the bottles immediately before consumption
by mixing the powder with water, and were asked to consume the product every day at
breakfast.</p></sec><sec id="sec1-3" sec-type="general"><title>Study design</title><p>The present study was a parallel, double-blind, randomised, placebo-controlled,
dose-finding study. After a screening visit and a run-in period of 1&#x02013;2 weeks, eligible
volunteers were randomly assigned by a computer-generated list to ten groups of ten
participants each, consuming either HMO or placebo daily for 2 weeks. A constant regimen
of 2&#x02032;FL, LNnT or 2&#x02032;FL+LNnT (2:1 mass ratio; mix) at 5, 10 or 20 g per d or 2 g of glucose
as placebo was allocated to each group. The daily doses were chosen to be within the range
of the average daily intake per kg body weight in infants<sup>(</sup>
<xref rid="ref46" ref-type="bibr">
<sup>46</sup>
</xref>
<sup>,</sup>
<xref rid="ref47" ref-type="bibr">
<sup>47</sup>
</xref>
<sup>)</sup>. Diet was not controlled, but subjects were asked not to change their diet
over the course of the study. Subjects had clinical check-ups at entry and at the end of
the intervention. Subjects taking the study product for &#x02265;12 of the 14 d of intervention
were considered compliant.</p></sec><sec id="sec1-4" sec-type="general"><title>Ethical considerations</title><p>This study was conducted according to the guidelines laid down in the Declaration of
Helsinki, and all procedures involving human subjects were approved by the Ethics
Committee in Region Zealand (registration number SJ-345). The trial was registered with
the Danish Data Protection authorities via the regional approval system, and Danish
regulations relating to personal data protection were respected. All subjects were given
oral and written information about the purpose and procedures of the study. Consent to
participate was signed by the subjects before the study started, and the subjects were
free to withdraw from the study at any time point without giving any explanation.</p></sec><sec id="sec1-5" sec-type="general"><title>Gastrointestinal symptoms and stool consistency</title><p>To evaluate the influence on GI symptoms, participants completed a self-administered GSRS
form, once at screening, once at entry and once at end of the intervention period. The
GSRS form includes fifteen items covering five dimensions: abdominal pain, indigestion,
reflux, diarrhoea and constipation<sup>(</sup>
<xref rid="ref48" ref-type="bibr">
<sup>48</sup>
</xref>
<sup>)</sup>. The participants rated severity using a seven-point Likert scale running
from (1) no discomfort to (7) very severe discomfort. Bowel movement frequency was
recorded daily, and stool consistency was evaluated using the Bristol Stool Form Scale
(BSFS)<sup>(</sup>
<xref rid="ref49" ref-type="bibr">
<sup>49</sup>
</xref>
<sup>)</sup>. The BSFS was filled in on a daily basis during the study period, from
screening to the end of the intervention. Adverse events, defined as any untoward medical
occurrence, including those that did not necessarily have a causal relationship with the
investigational or placebo products, were reported from intake of the first dose and
throughout the intervention period.</p></sec><sec id="sec1-6" sec-type="general"><title>Blood analysis</title><p>Blood samples for routine clinical chemistry and haematology analyses were collected at
screening and at the end of the intervention to assess the safety of study product intake.
Samples were analysed for Hb, erythrocytes, haematocrit, leucocytes, thrombocytes,
creatinine, Na, K, alanine aminotransferase, alkaline phosphatases, coagulation factor II,
VII and X, bilirubin, albumin, C-reactive protein and glucose. Blood samples for the
analysis of additional biomarkers were collected at study entry and at the end of the
intervention. These samples were analysed for HbA1c, apoA1, apoB, transferrin,
progesterone, cortisol, oestradiol, IL-10, IL-6, TNF-<italic>&#x003b1;</italic>, blood urea
nitrogen, Fe, TAG, HDL-cholesterol, LDL-cholesterol, total free fatty acids, insulin,
lysozyme, testosterone and glucagon (Unilabs A/S).</p></sec><sec id="sec1-7" sec-type="general"><title>Faecal biomarkers</title><p>Faecal samples for biomarker analysis were collected just before study entry and at the
end of the intervention. ELISA was applied to determine calprotectin (B&#x000fc;hlmann
Laboratories) and secretory IgA levels (Bethyl Laboratories). SCFA were analysed as
described previously<sup>(</sup>
<xref rid="ref32" ref-type="bibr">
<sup>32</sup>
</xref>
<sup>)</sup>. In brief, faecal samples were solubilised in 5 volumes of water, spiked with
10 m<sc>m</sc>-succinic acid and extracted twice in diethylether for 20 min at room
temperature. The final supernatants were passed through a 0&#x000b7;45-&#x003bc;m filter and analysed by
HPLC. The HPLC system (Lachrom L7100; Merck-Hitachi) included a HPX-87H Aminex column
(300&#x000d7;7&#x000b7;8 mm, from BioRad) and guard column of the same type. Chromatography was performed
at 30&#x000b0;C isocratically in 10-m<sc>m</sc>-H<sub>2</sub>SO<sub>4</sub>, which was the mobile
phase, at a flow rate of 0&#x000b7;4 ml/min. SCFA were detected at 210 nm in a UV detector, and
concentrations calculated from the peak areas were compared with authentic standards.</p></sec><sec id="sec1-8" sec-type="general"><title>Faecal DNA preparation</title><p>Faecal microbiota composition was analysed using four faecal samples per subject, with
approximately 1 week between each sampling. Samples 1 and 2 were collected before
intervention start, and samples 3 and 4 were collected during the intervention. For the
analysis, the average of samples 1 and 2 was used as the baseline value and the average of
samples 3 and 4 was for the intervention. The faecal samples were collected by the
participants, and immediately stored in a freezer (about &#x02212;20&#x000b0;C). When delivered to the
hospital (in cooling kits), samples were stored at &#x02212;80&#x000b0;C until analysis. DNA was extracted
using the ninety-six-well PowerSoil DNA Isolation Kit (MO-BIO).</p></sec><sec id="sec1-9" sec-type="general"><title>16S rRNA sequencing</title><p>The V3&#x02013;V4 region of the 16S rDNA was amplified using the forward primer
S-D-Bact-0341-b-S-17 (5&#x02032;-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG-3&#x02032;) and the reverse primer
S-D-Bact-0785-a-A-21 (5&#x02032;-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG-3&#x02032;)<sup>(</sup>
<xref rid="ref50" ref-type="bibr">
<sup>50</sup>
</xref>
<sup>)</sup>, with Illumina adapters attached. The following PCR programme was used: 98&#x000b0;C
for 30 s, 25&#x000d7; (98&#x000b0;C for 10 s, 55&#x000b0;C for 20 s, 72&#x000b0;C for 20 s) and 72&#x000b0;C for 5 min; Nextera
Index Kit V2 (Illumina) indices were added in an identical PCR with only eight cycles.
Products from the PCR reactions were cleaned using the SequalPrep Normalization Plate Kit
(Invitrogen) or Agencourt AMPure XP PCR purification kit (Beckman Coulter) and pooled.
Sequencing was carried out on an Illumina MiSeq sequencer using the MiSeq Reagent Kit V3
(Illumina) for 2&#x000d7; 300-bp paired-end sequencing.</p></sec><sec id="sec1-10" sec-type="general"><title>Bioinformatical analysis</title><p>The paired-end reads were merged, and low-quality sequences were discarded (truncating
reads at a quality score of 4 or less and requiring 100-bp overlap between paired reads,
perfect match to primers, a merged sequence length of 300&#x02013;600 bp, a maximum of five
expected errors and a minimum of 5 identical sequences in the data set). Sequences were
clustered into operational taxonomic units (OTU) at 97 % sequence similarity using
USEARCH<sup>(</sup>
<xref rid="ref51" ref-type="bibr">
<sup>51</sup>
</xref>
<sup>)</sup>, and suspected chimeric sequences were discarded on the basis of UCHIME<sup>(</sup>
<xref rid="ref52" ref-type="bibr">
<sup>52</sup>
</xref>
<sup>)</sup>. Taxonomic assignment of OTU was performed on the basis of comparison with a
database of curated sequences derived from the Ribosomal Database Project<sup>(</sup>
<xref rid="ref53" ref-type="bibr">
<sup>53</sup>
</xref>
<sup>)</sup>. Samples were rarified to the lowest sequence number found in a sample (11
568 sequences). Both negative controls and mock communities were included in the analysis
as quality controls.</p></sec><sec id="sec1-11" sec-type="general"><title>Statistical analysis</title><p>All participants completed the study as per protocol, and were included in the
statistical analysis. Differences in GSRS scores, BSFS scores, biomarker and clinical
chemistry, and haematology were analysed.</p><p>Analysis of difference between baseline and end of intervention in the microbiota
profile, within each intervention group, was performed using the Mann&#x02013;Whitney
<italic>U</italic> tests using Bonferroni&#x02019;s correction for multiple hypothesis testing.</p><p>Generalised UniFrac distances<sup>(</sup>
<xref rid="ref54" ref-type="bibr">
<sup>54</sup>
</xref>
<sup>)</sup> between samples were calculated at <italic>&#x003b1;</italic>=0&#x000b7;5 and with phyla
abundance overlaid on the plots.</p><p>Change in sequence abundance (delta (end&#x02212;entry)) was calculated, and a one-way ANOVA with
Fisher&#x02019;s LSD as <italic>post hoc</italic> test was used to compare the statistical
difference in the change in Actinobacteria and bifidobacteria, and the three most dominant
OTU identified within the <italic>Bifidobacterium</italic> genus comparing placebo with
each intervention group. Difference in SCFA concentration at entry and end of intervention
was analysed using a two-way repeated measures ANOVA. Non-parametric tests were used when
data were not normally distributed as tested using the Shapiro&#x02013;Wilk normality test.
Multiple comparisons using Pearson&#x02019;s correlation coefficient were calculated for SCFA and
bifidobacteria, testing separately the groups taking 5, 10 or 20 g of HMO using Prism 6
(GraphPad Prism, version 6.05). In all cases, statistically significant differences were
established at <italic>P</italic>&#x0003c;0&#x000b7;05.</p></sec></sec><sec sec-type="results" id="sec2"><title>Results</title><sec id="sec2-1" sec-type="general"><title>Safety and tolerance of 2&#x02032;-<italic>O</italic>-fucosyllactose and
lacto-<italic>N</italic>-neotetraose supplementation</title><p>In total, 100 healthy, adult volunteers (forty-nine females and fifty-one males) aged
19&#x02013;57 years were enrolled in the study. Demographic parameters such as age, sex and BMI
did not differ between groups at entry (<xref ref-type="table" rid="tab1">Table 1</xref>).
All subjects were examined physically at screening and at end of intervention. No change
in clinical significance in any physical parameter including pulse rate and blood pressure
was found during the 2-week intervention. To further assess the safety of HMO
supplementation, blood samples were collected before and after intervention for routine
clinical chemistry and haematology analyses. These analyses revealed no irregularities
considered due to the intake of study products in any intervention group (online
Supplementary Table S1), thus confirming the safety of the tested compounds.<table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Participant demographics at entry (Mean values and standard deviations; means and
ranges)</p></caption><alternatives><graphic xlink:href="S0007114516003354_tab1"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="6">2&#x02032;FL</th><th align="center" rowspan="1" colspan="6">LNnT</th><th align="center" rowspan="1" colspan="6">Mix</th><th align="center" rowspan="1" colspan="2"/></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="2">20 g</th><th align="center" rowspan="1" colspan="2">10 g</th><th align="center" rowspan="1" colspan="2">5 g</th><th align="center" rowspan="1" colspan="2">20 g</th><th align="center" rowspan="1" colspan="2">10 g</th><th align="center" rowspan="1" colspan="2">5 g</th><th align="center" rowspan="1" colspan="2">20 g</th><th align="center" rowspan="1" colspan="2">10 g</th><th align="center" rowspan="1" colspan="2">5 g</th><th align="center" rowspan="1" colspan="2">Placebo</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Mean</th><th align="left" rowspan="1" colspan="1">
<sc>sd</sc>
</th><th align="left" rowspan="1" colspan="1">Mean</th><th align="left" rowspan="1" colspan="1">
<sc>sd</sc>
</th><th align="left" rowspan="1" colspan="1">Mean</th><th align="left" rowspan="1" colspan="1">
<sc>sd</sc>
</th><th align="left" rowspan="1" colspan="1">Mean</th><th align="left" rowspan="1" colspan="1">
<sc>sd</sc>
</th><th align="left" rowspan="1" colspan="1">Mean</th><th align="left" rowspan="1" colspan="1">
<sc>sd</sc>
</th><th align="left" rowspan="1" colspan="1">Mean</th><th align="left" rowspan="1" colspan="1">
<sc>sd</sc>
</th><th align="left" rowspan="1" colspan="1">Mean</th><th align="left" rowspan="1" colspan="1">
<sc>sd</sc>
</th><th align="left" rowspan="1" colspan="1">Mean</th><th align="left" rowspan="1" colspan="1">
<sc>sd</sc>
</th><th align="left" rowspan="1" colspan="1">Mean</th><th align="left" rowspan="1" colspan="1">
<sc>sd</sc>
</th><th align="left" rowspan="1" colspan="1">Mean</th><th align="left" rowspan="1" colspan="1">
<sc>sd</sc>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">27&#x000b7;8</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">7&#x000b7;4</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">24&#x000b7;7</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;9</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">25&#x000b7;8</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">4&#x000b7;2</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">24&#x000b7;9</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">4&#x000b7;9</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">25&#x000b7;0</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">5&#x000b7;5</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">24&#x000b7;8</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">4&#x000b7;4</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">22&#x000b7;4</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;8</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">26&#x000b7;5</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;8</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">24&#x000b7;8</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;6</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">26&#x000b7;8</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">6&#x000b7;3</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"> Mean</td><td align="char" char="&#x000b7;" rowspan="1" colspan="2">39&#x000b7;9</td><td align="center" rowspan="1" colspan="2">33&#x000b7;4</td><td align="center" rowspan="1" colspan="2">38&#x000b7;3</td><td align="center" rowspan="1" colspan="2">39&#x000b7;0</td><td align="center" rowspan="1" colspan="2">34&#x000b7;8</td><td align="center" rowspan="1" colspan="2">34&#x000b7;6</td><td align="center" rowspan="1" colspan="2">29&#x000b7;3</td><td align="center" rowspan="1" colspan="2">37&#x000b7;1</td><td align="center" rowspan="1" colspan="2">38&#x000b7;9</td><td align="center" rowspan="1" colspan="2">34&#x000b7;9</td></tr><tr><td align="left" rowspan="1" colspan="1"> Range</td><td align="center" rowspan="1" colspan="2">25&#x02013;55</td><td align="center" rowspan="1" colspan="2">21&#x02013;51</td><td align="center" rowspan="1" colspan="2">27&#x02013;52</td><td align="center" rowspan="1" colspan="2">22&#x02013;57</td><td align="center" rowspan="1" colspan="2">23&#x02013;51</td><td align="center" rowspan="1" colspan="2">26&#x02013;47</td><td align="center" rowspan="1" colspan="2">19&#x02013;45</td><td align="center" rowspan="1" colspan="2">19&#x02013;56</td><td align="center" rowspan="1" colspan="2">23&#x02013;53</td><td align="center" rowspan="1" colspan="2">25&#x02013;47</td></tr><tr><td align="left" rowspan="1" colspan="1">Males/females</td><td align="center" rowspan="1" colspan="2">4/6</td><td align="center" rowspan="1" colspan="2">5/5</td><td align="center" rowspan="1" colspan="2">4/6</td><td align="center" rowspan="1" colspan="2">4/6</td><td align="center" rowspan="1" colspan="2">4/6</td><td align="center" rowspan="1" colspan="2">9/1</td><td align="center" rowspan="1" colspan="2">8/2</td><td align="center" rowspan="1" colspan="2">4/6</td><td align="center" rowspan="1" colspan="2">6/4</td><td align="center" rowspan="1" colspan="2">3/7</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>2&#x02032;FL, 2&#x02032;-<italic>O</italic>-fucosyllactose; LNnT,
lacto-<italic>N</italic>-neotetraose; Mix, 2&#x02032;FL:LNnT (2:1).</p></fn></table-wrap-foot></table-wrap>
</p><p>Compliance was defined as ingestion of the study product for &#x02265;12 days during the
intervention period. All subjects were compliant and completed the study according to the
protocol without any dropouts (<xref ref-type="fig" rid="fig1">Fig. 1</xref>). A total of
fifty-six adverse events were reported by forty-four subjects. All were judged as &#x02018;mild&#x02019;,
and all subjects tolerated the investigational products throughout the trial period.
Adverse events were usually reported as a complex of multiple symptoms such as flatulence,
bloating and constipation, and were primarily reported at the end of the 2-week
intervention. Most adverse events were reported by subjects taking the highest doses of
2&#x02032;FL and LNnT. Gas/flatulence was the most common adverse event reported, followed by
stomach pain, diarrhoea/loose stools and rumbling, but at lower frequencies.<fig id="fig1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Flow chart of the study. A total of 110 healthy, adult volunteers were screened for
eligibility to participate in the study; 100 of them were randomised to one of the
following intervention groups: 2&#x02032;-<italic>O</italic>-fucosyllactose (2&#x02032;FL),
lacto-<italic>N</italic>-neotetraose (LNnT) or 2:1 mix of 2&#x02032;FL:LNnT, each in three
daily doses of 5, 10 or 20 g, or 2 g glucose as placebo. GSRS, gastrointestinal
symptom rating scale.</p></caption><graphic xlink:href="S0007114516003354_fig1"/></fig>
</p><p>GI symptoms were assessed before, during and at the end of the intervention using a
self-administered GSRS questionnaire covering symptoms related to abdominal pain,
indigestion, reflux, diarrhoea and constipation. The GSRS scores were low at baseline,
reflecting exclusion criteria, and remained low after intervention. Compared with
baseline, the changes in GSRS scores within an intervention group were generally not
significant, with a few exceptions: volunteers taking the high 20-g dose of 2&#x02032;FL and LNnT
reported increased bloating and passing of gas. Those receiving 20 g of 2&#x02032;FL further
reported increased rumbling, whereas those on 20 g of LNnT reported harder stools.
Increases in passing gas were also reported by those receiving 10 g of LNnT. Compared with
placebo, most of the changes in GSRS scores were insignificant, again with the exception
of the intervention group receiving the highest dose of 2&#x02032;FL, who reported increased
nausea, rumbling, bloating, passing of gas, diarrhoea, loose stools and urgency to pass
stools, and the groups receiving the high 20-g dose and intermediate 10-g dose of LNnT,
who reported increased passing of gas after 2 weeks of intervention (<xref ref-type="fig" rid="fig2">Fig. 2</xref>). Despite statistical significance, mean scores remained low
(mean score&#x0003c;3; mild discomfort or below). No significant changes in GSRS were found
in subjects receiving the highest dose of the mix.<fig id="fig2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Gastrointestinal symptom rating scale (GSRS) scores at the end of the intervention.
Scores ranged from 1 (no discomfort) to 7 (very severe discomfort). (a)
2&#x02032;-<italic>O</italic>-fucosyllactose (2&#x02032;FL) supplementation groups and placebo
group; (b) lacto-<italic>N</italic>-neotetraose (LNnT) supplementation groups and
placebo group; (c) 2&#x02032;FL:LNnT (2:1) mix supplementation groups and placebo group.
<inline-graphic xlink:href="S0007114516003354_inline1.jpg" mime-subtype="gif"/>, 20 g, <inline-graphic xlink:href="S0007114516003354_inline2.jpg" mime-subtype="gif"/>,
10 g, <inline-graphic xlink:href="S0007114516003354_inline3.jpg" mime-subtype="gif"/>, 5 g, <inline-graphic xlink:href="S0007114516003354_inline4.jpg" mime-subtype="gif"/>, placebo. GSRS scores
at the end of intervention for placebo and the intervention group were compared
using a two-way ANOVA and Bonferroni&#x02019;s multiple comparisons correction. *
Significantly different between the intervention group and the placebo group
(<italic>P</italic>&#x0003c;0&#x000b7;05).</p></caption><graphic xlink:href="S0007114516003354_fig2"/></fig>
</p><p>Generally, the interventions had a minor impact on stool frequency and consistency (<xref ref-type="table" rid="tab2">Table 2</xref>). The average number of daily bowel movements
was significantly increased at the end of the intervention in groups taking 20 g of 2&#x02032;FL,
20 g of LNnT and 5 g of LNnT compared with baseline; however, the differences were small
(an extra 0&#x000b7;3 bowel movement/d) and deemed clinically irrelevant. When comparing the
intervention groups with the placebo, no significant difference in bowel movement was
observed. Subjects taking the high 20-g dose of 2&#x02032;FL or LNnT reported significantly higher
BSFS scores (indicating softer stools), after the intervention compared with baseline.
However, the differences were small (&#x0003c;0&#x000b7;5 points increase). In addition, a number
of blood and faecal biomarkers were measured, and safety of the HMO supplementation was
confirmed at the level of clinical chemistry and haematology. All parameters measured
remained within the normal range throughout the intervention. Although a few differences
were statistically significant (online Supplementary Table S1), they were not considered
to be clinically relevant. Taken together, these data demonstrated that dietary
supplementation with high doses of 2&#x02032;FL and LNnT is safe and well tolerated and resulted
in 100 % compliance.<table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Stool characteristics during the 2 week intervention for healthy adult volunteers
(Grand mean values and standard deviations of BSFS recorded daily during the
screening period (before) and during (after) the intervention)<xref ref-type="fn" rid="tab2fn1">&#x02020;</xref>
</p></caption><alternatives><graphic xlink:href="S0007114516003354_tab2"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="6">2&#x02032;FL</th><th align="center" rowspan="1" colspan="6">LNnT</th><th align="center" rowspan="1" colspan="6">Mix</th><th align="center" rowspan="1" colspan="2"/></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="2">20 g</th><th align="center" rowspan="1" colspan="2">10 g</th><th align="center" rowspan="1" colspan="2">5 g</th><th align="center" rowspan="1" colspan="2">20 g</th><th align="center" rowspan="1" colspan="2">10 g</th><th align="center" rowspan="1" colspan="2">5 g</th><th align="center" rowspan="1" colspan="2">20 g</th><th align="center" rowspan="1" colspan="2">10 g</th><th align="center" rowspan="1" colspan="2">5 g</th><th align="center" rowspan="1" colspan="2">Placebo</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sd</sc>
</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sd</sc>
</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sd</sc>
</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sd</sc>
</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sd</sc>
</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sd</sc>
</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sd</sc>
</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sd</sc>
</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sd</sc>
</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">
<sc>sd</sc>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Bowel movement</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"> B</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;3</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;3</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;4</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;6</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;4</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;6</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;4</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;5</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;5</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;6</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;3</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;2</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;2</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;4</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;3</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;5</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;4</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;6</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;2</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;3</td></tr><tr><td align="left" rowspan="1" colspan="1"> A</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;6*</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;4</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;6</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;8</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;3</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;4</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;7*</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;6</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;6</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;7</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;6*</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;3</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;4</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;5</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;4</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;6</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;3</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;5</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;3</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;4</td></tr><tr><td align="left" rowspan="1" colspan="1">Stool consistency</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"> B</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;5</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;7</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;9</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;8</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;7</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;8</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;6</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;7</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;8</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;3</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">4&#x000b7;0</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;7</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;8</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;6</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;7</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;7</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">4&#x000b7;1</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;8</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;9</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;8</td></tr><tr><td align="left" rowspan="1" colspan="1"> A</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">4&#x000b7;0*</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;5</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">4&#x000b7;0</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;7</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;8</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;6</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;9*</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;8</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;8</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;5</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">4&#x000b7;1</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;8</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;7</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;9</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">4&#x000b7;0</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;6</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">4&#x000b7;5</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;9</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;9</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;8</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>2&#x02032;FL, 2&#x02032;-<italic>O</italic>-fucosyllactose; LNnT,
lacto-<italic>N</italic>-neotetraose; Mix, 2&#x02032;FL:LNnT (2:1); B, before; A, after.</p><p>* The difference in stool characteristics from before and after intervention for
each individual group was determined using Wilcoxon&#x02019;s signed-rank test
(<italic>P</italic>&#x0003c;0&#x000b7;05).</p></fn><fn id="tab2fn1"><label>&#x02020;</label><p>Bowel movement: number of daily bowel movements. Stool consistency: measured with
the Bristol Stool Form Scale (1=hard lumps; 7=liquid stools).</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec id="sec2-2" sec-type="general"><title>Microbiota profiling and bacterial metabolites</title><p>Sequencing of the 16S rRNA V3&#x02013;V4 regions yielded 123 283 020 paired-end reads, which
resulted in 19 718 714 sequences after quality filtration and chimera removal distributed
over 400 samples. Taxonomic assignment of OTU was done, and after this samples were
rarified to the lowest sequence number found in a sample, which was 11 568 sequences. The
two samples collected before the intervention were counted as one group, assigned before.
The two samples collected at 1 and 2 weeks after intervention were also counted as one
group, assigned after.</p><p>Before the intervention, a plot of the UniFrac distances showed no easily discernible
pattern to discriminate between the different intervention groups (<xref ref-type="fig" rid="fig3">Fig. 3(a)</xref>). However, after the intervention (<xref ref-type="fig" rid="fig3">Fig. 3(b)</xref>), the groups receiving HMO appeared to be differentiated
from placebo based on the abundance of Actinobacteria, with the intervention groups
receiving higher doses of HMO having greater sequence abundance of Actinobacteria (<xref ref-type="fig" rid="fig3">Fig. 3</xref>). Compared with baseline, the increase in the
relative abundance of Actinobacteria was statistically significant for all groups taking
LNnT, the high 20-g dose and the intermediate 10-g dose of the mix and for the groups
taking the low 5-g dose and the intermediate 10-g dose of 2&#x02032;FL (<xref ref-type="fig" rid="fig4">Fig. 4</xref>). Surprisingly, this effect was not observed in those taking
the high dose of 2&#x02032;FL. The increase in Actinobacteria sequence abundance was dose
dependent, especially when excluding 20 g 2&#x02032;FL: a multiple linear regression using data
from all but this treatment group found that there was a significant positive correlation
between the concentration of the two HMO and the increase in Actinobacteria
(<italic>P</italic>&#x0003c;0&#x000b7;05, <italic>R</italic>
<sup>2</sup>=28 %) with LNnT and 2&#x02032;FL having similar coefficients (0&#x000b7;008 and 0&#x000b7;011,
respectively).<fig id="fig3" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>Principal coordinates analysis plot of generalised UniFrac distances for all
samples collected. (a) Before intervention and (b) after intervention. Phyla
abundances are overlaid in blue. Samples are divided into intervention groups with
the label at the centre of gravity for each group. Before intervention, there is no
clear pattern. After intervention, the human milk oligosaccharide supplementation
groups followed an axis of increasing Actinobacteria and decreasing Firmicutes for
increasing doses.</p></caption><graphic xlink:href="S0007114516003354_fig3"/></fig>
<fig id="fig4" orientation="portrait" position="float"><label>Fig. 4</label><caption><p>Relative abundance of faecal bacteria at the phylum level. (a and b) Phyla level in
the three 2&#x02032;-<italic>O</italic>-fucosyllactose (2&#x02032;FL) groups receiving 5, 10 or 20 g
and placebo before and after intervention; (c and d) phyla level in the three
lacto-<italic>N</italic>-neotetraose (LNnT) groups receiving 5, 10 or 20 g and
placebo before and after intervention; (e and f) phyla level in the three mix groups
receiving 5, 10 or 20 g of 2&#x02032;FL:LNnT (2:1) and placebo before and after
intervention. * Significantly different between before and after intervention
(<italic>P</italic>&#x0003c;0&#x000b7;05). <inline-graphic xlink:href="S0007114516003354_inline5.jpg" mime-subtype="gif"/>, Actinobacteria;
<inline-graphic xlink:href="S0007114516003354_inline6.jpg" mime-subtype="gif"/>, Bacteroidetes; <inline-graphic xlink:href="S0007114516003354_inline7.jpg" mime-subtype="gif"/>,
Firmicutes; <inline-graphic xlink:href="S0007114516003354_inline8.jpg" mime-subtype="gif"/>, Proteobacteria; <inline-graphic xlink:href="S0007114516003354_inline9.jpg" mime-subtype="gif"/>,
others.</p></caption><graphic xlink:href="S0007114516003354_fig4"/></fig>
</p><p>HMO supplementation also affected other phyla such as Firmicutes, which decreased after
the high dose of LNnT and the mix, and Proteobacteria, which decreased after the
intermediate dose of 2&#x02032;FL (<xref ref-type="fig" rid="fig4">Fig. 4</xref>). The HMO
intervention led to reduced relative abundance of Firmicutes and Proteobacteria. This
phylum includes pathobionts such as <italic>Enterobacteriaceae</italic>.</p><p>At the lower taxonomic level, the increase in Actinobacteria could be fully explained by
the increase in <italic>Bifidobacterium</italic>, as this genus showed equal changes in
sequence abundance as at the phylum level (<xref ref-type="fig" rid="fig5">Fig. 5</xref>).
The <italic>Bifidobacterium</italic> abundance was significantly increased compared with
placebo for groups taking 10 g of 2&#x02032;FL, 5, 10 or 20 g of LNnT, and 10 or 20 g of the mix.
In total, 77 % of the participants responded to the HMO interventions. We defined a
responder as a participant having an increase in sequence abundance of
<italic>Bifidobacterium</italic> &#x0003e;10 %. There was no statistically significant
association, indicating that the initial abundance of <italic>Bifidobacterium</italic>
determined whether an individual was a responder or non-responder to the bifidogenic
effect of 2&#x02032;FL and LNnT (Mann&#x02013;Whitney test, <italic>P</italic>=0&#x000b7;359). In addition, no
correlation could be observed between initial abundance and change in bifidobacteria
(linear regression, <italic>r</italic>
<sup>2</sup>=0&#x000b7;016; <italic>P</italic>=0&#x000b7;284). Three dominant OTU (s1_r64, s1_r2031 and
s1_r379) belonging to <italic>Bifidobacterium</italic> were affected by HMO
supplementation. The changes in abundance of these OTU are shown in <xref ref-type="fig" rid="fig6">Fig. 6</xref>. The OTU most affected by HMO supplementation was s1_r64. The
abundance of this OTU increased after HMO intervention. Compared with placebo, this change
was statistically significant for groups taking 10 g of 2&#x02032;FL and 10 or 20 g of LNnT or
mix. The abundance of s1_r2031 increased significantly compared with placebo only for
those taking 20 g of the mix. The three OTU were identified using Blastn and showed high
sequence similarity to <italic>B. adolescentis</italic> (&#x0003e;99 %) for s1_r64, to
<italic>B. longum</italic> (&#x0003e;99 %) for s1_r2031 and to <italic>B.
bifidum</italic> (&#x0003e;99 %) for s1_r379. The effect of the HMO intervention on
eighteen selected genera &#x02013; <italic>Bifidobacterium</italic>, <italic>Bacteroides</italic>,
<italic>Barnesiella</italic>, <italic>Parabacteroides</italic>,
<italic>Prevotella</italic>, <italic>Alistipes</italic>, <italic>Lactobacillus</italic>,
<italic>Eubacterium</italic>, <italic>Blautia</italic>, <italic>Coprococcus</italic>,
<italic>Dorea</italic>, <italic>Lachnospiracea incertae sedis</italic>,
<italic>Roseburia</italic>, <italic>Faecalibacterium</italic>,
<italic>Ruminococcus</italic>, <italic>Dialister</italic>,
<italic>Escherichia/Shigella</italic> and <italic>Akkermansia &#x02013;</italic> associated with
health or disease in obesity, irritable bowel syndrome or inflammatory bowel disease<sup>(</sup>
<xref rid="ref55" ref-type="bibr">
<sup>55</sup>
</xref>
<sup>&#x02013;</sup>
<xref rid="ref57" ref-type="bibr">
<sup>57</sup>
</xref>
<sup>)</sup> was examined. As shown in <xref ref-type="fig" rid="fig7">Fig. 7</xref>, 10 g
of HMO did not affect the relative abundance of these genera other than
<italic>Bifidobacterium</italic> during the 2 weeks of intervention. Similar results
were observed for the other two doses &#x02013; 5 and 20 g (data not shown). For the placebo
group, none of the eighteen genera changed. Despite shifts in microbial composition, no
significant difference in the SCFA acetate, butyrate or propionate was observed after 2
weeks of intervention (<xref ref-type="fig" rid="fig8">Fig. 8</xref>). Pearson&#x02019;s
correlation was applied to determine the relationship between bifidobacteria and SCFA
concentration. A positive correlation was found between propionate and bifidobacteria in
those taking 10 g of HMO (<italic>r</italic> 0&#x000b7;418; <italic>P</italic>&#x0003c;0&#x000b7;05). The
opposite was found for subjects taking 5 g of HMO, where a negative correlation was
obtained between acetate or propionate and bifidobacteria (<italic>r</italic> &#x02212;0&#x000b7;357;
<italic>P</italic>&#x0003c;0&#x000b7;05 or <italic>r</italic> &#x02212;0&#x000b7;404;
<italic>P</italic>&#x0003c;0&#x000b7;05, respectively). In breast-fed infants,
<italic>Bifidobacterium</italic> species such as <italic>B. longum</italic> subsp.
<italic>infantis</italic>, <italic>B. breve</italic> and <italic>B. bifidum</italic>
dominate. In this adult study, we determined that particularly one OTU (s1_r64) with high
sequence similarity to <italic>B. adolescentis</italic> is the main responder to 2&#x02032;FL and
LNnT supplementation.<fig id="fig5" orientation="portrait" position="float"><label>Fig. 5</label><caption><p>Change in sequence abundance of Actinobacteria (a) and
<italic>Bifidobacterium</italic> (b). The box represents the median and the 25th to
75th percentiles. The whiskers represent the smallest and largest changes observed.
* Significantly different between the intervention group and the placebo group
(<italic>P</italic>&#x0003c;0&#x000b7;05). 2&#x02032;FL, 2&#x02032;-<italic>O</italic>-fucosyllactose;
LNnT, lacto-<italic>N</italic>-neotetraose; Mix, 2&#x02032;FL:LNnT (2:1).</p></caption><graphic xlink:href="S0007114516003354_fig5"/></fig>
<fig id="fig6" orientation="portrait" position="float"><label>Fig. 6</label><caption><p>Change in sequence abundance of three operational taxonomic units (OTU) showing
high similarity to the described <italic>Bifidobacterium</italic> species,
<italic>B. adolescentis</italic>, <italic>B. longum</italic> and <italic>B.
bifidum</italic>. The box represents the median and the 25th to 75th percentiles.
The whiskers represent the smallest and largest changes observed. * Significantly
different between the intervention group and the placebo group
(<italic>P</italic>&#x0003c;0&#x000b7;05). 2&#x02032;FL, 2&#x02032;-<italic>O</italic>-fucosyllactose; LNnT,
lacto-<italic>N</italic>-neotetraose; Mix, 2&#x02032;FL:LNnT (2:1). <inline-graphic xlink:href="S0007114516003354_inline10.jpg" mime-subtype="gif"/>,
<italic>s1_r64</italic>; <inline-graphic xlink:href="S0007114516003354_inline11.jpg" mime-subtype="gif"/>, <italic>s1_r2031</italic>;
<inline-graphic xlink:href="S0007114516003354_inline12.jpg" mime-subtype="gif"/>, <italic>s1_r379</italic>.</p></caption><graphic xlink:href="S0007114516003354_fig6"/></fig>
<fig id="fig7" orientation="portrait" position="float"><label>Fig. 7</label><caption><p>Relative abundance of faecal bacteria at the genus level from before and after
intervention. The eighteen genera, <italic>Bifidobacterium</italic>,
<italic>Bacteroides</italic>, <italic>Barnesiella</italic>,
<italic>Parabacteroides</italic>, <italic>Prevotella</italic>,
<italic>Alistipes</italic>, <italic>Lactobacillus</italic>,
<italic>Eubacterium</italic>, <italic>Blautia</italic>,
<italic>Coprococcus</italic>, <italic>Dorea</italic>, <italic>Lachnospiracea
incertae sedis</italic>, <italic>Roseburia</italic>,
<italic>Faecalibacterium</italic>, <italic>Ruminococcus</italic>,
<italic>Dialister</italic>, <italic>Escherichia/Shigella</italic> and
<italic>Akkermansia</italic>, selected have been associated with obesity,
irritable bowel syndrome or inflammatory bowel disease. (a) The mean of relative
abundance of eighteen genera from the three intervention groups given 10 g of human
milk oligosaccharide (HMO). (b) Relative abundance of eighteen genera from the
placebo. Values are means, with their standard errors represented by vertical bars.
Multiple <italic>t</italic> test was performed followed by a calculation of false
discovery rate indicated as an adjusted <italic>P</italic>-value. * Significantly
different between the groups (<italic>P</italic>&#x0003c;0&#x000b7;05). Lachn_inc_sedis,
<italic>Lachnospiracea incertae sedis</italic>; <inline-graphic xlink:href="S0007114516003354_inline11.jpg" mime-subtype="gif"/>,
Before; <inline-graphic xlink:href="S0007114516003354_inline10.jpg" mime-subtype="gif"/>, after.</p></caption><graphic xlink:href="S0007114516003354_fig7"/></fig>
<fig id="fig8" orientation="portrait" position="float"><label>Fig. 8</label><caption><p>SCFA in faeces. Concentrations are given as m<sc>m/</sc>g faeces of acetate (a),
butyrate (b) and propionate (c) in samples from each intervention group and placebo
before (<inline-graphic xlink:href="S0007114516003354_inline11.jpg" mime-subtype="gif"/>) and after (<inline-graphic xlink:href="S0007114516003354_inline13.jpg" mime-subtype="gif"/>)
intervention. The box represents the median and the 25th to 75th percentiles. The
whiskers represent the smallest and largest concentrations measured. 2&#x02032;FL,
2&#x02032;-<italic>O</italic>-fucosyllactose; LNnT, lacto-<italic>N</italic>-neotetraose;
Mix, 2&#x02032;FL:LNnT (2:1).</p></caption><graphic xlink:href="S0007114516003354_fig8"/></fig>
</p></sec></sec><sec id="sec3"><title>Discussion and conclusion</title><p>This study provides the first assessment on the safety, tolerance and influence on adult
gut microbiota populations of 2&#x02032;FL, LNnT and a mix of 2&#x02032;FL and LNnT. All 100 healthy, adult
participants completed the study according to the protocol, without any premature
discontinuation, thus demonstrating that the daily uptake of up to 20 g of the HMO 2&#x02032;FL and
LNnT is perfectly safe in adults.</p><p>Blood safety assessments and physical examinations revealed no irregularities considered
due to intake of the study products in any intervention group. Adverse events reported
related mainly to GI symptoms, particularly gas/flatulence, and were characterised as mild.
The relationship between the reported adverse events to intake of the study products was
mainly described as &#x02018;possible&#x02019;. However, as many of the symptoms reported were common GI
symptoms, it was difficult to judge whether the symptoms were actually related to the study
product or to normal day-to-day variation or increased awareness of GI symptoms during the
trial period. In all, the study raised no safety concerns. Preclinical toxicology studies of
chemically produced 2&#x02032;FL and LNnT have previously confirmed the safety of intake<sup>(</sup>
<xref rid="ref44" ref-type="bibr">
<sup>44</sup>
</xref>
<sup>,</sup>
<xref rid="ref45" ref-type="bibr">
<sup>45</sup>
</xref>
<sup>)</sup>, and an EFSA panel on Dietetic Products, Nutrition and Allergies (NDA) has
further assessed and concluded that 2&#x02032;FL and LNnT as produced by Glycom A/S are safe for use
in foods<sup>(</sup>
<xref rid="ref46" ref-type="bibr">
<sup>46</sup>
</xref>
<sup>,</sup>
<xref rid="ref47" ref-type="bibr">
<sup>47</sup>
</xref>
<sup>)</sup>.</p><p>HMO as a part of breast milk are well tolerated by infants even at high doses, because the
mother&#x02019;s milk contains 5&#x02013;25 g/l of HMO<sup>(</sup>
<xref rid="ref18" ref-type="bibr">
<sup>18</sup>
</xref>
<sup>)</sup>. However, the adult tolerance to high bolus doses of selected HMO was unknown
before this study. The doses used were selected from a safety and tolerance perspective and
based on the average daily intake of 2&#x02032;FL and LNnT in infants. The intake of 2&#x02032;FL can be
approximated to 170&#x02013;660 mg/kg body weight per d and potentially up to 1150 mg/kg body weight
per d<sup>(</sup>
<xref rid="ref46" ref-type="bibr">
<sup>46</sup>
</xref>
<sup>)</sup>, and the intake of LNnT can be approximated to 20&#x02013;100 mg/kg body weight per d
and potentially up to 385 mg/kg body weight per d<sup>(</sup>
<xref rid="ref47" ref-type="bibr">
<sup>47</sup>
</xref>
<sup>)</sup>. On a 70-kg body weight basis for adults, these values correspond to 12&#x02013;46 g
2&#x02032;FL per d and potentially up to 80 g per d and 1&#x000b7;4&#x02013;7 g of LNnT per d and potentially up to
27 g LNnT per d. The maximum 20 g per daily bolus dose was selected after comparison with
other prebiotic oligosaccharides that are commonly used in adult applications and that
typically show pronounced tolerability issues beyond this dose<sup>(</sup>
<xref rid="ref58" ref-type="bibr">
<sup>58</sup>
</xref>
<sup>)</sup>. The infant intestinal microbiota is very different from that of the adult and
contains greater abundance of bacteria, particularly bifidobacteria, which are known to
metabolise HMO<sup>(</sup>
<xref rid="ref37" ref-type="bibr">
<sup>37</sup>
</xref>
<sup>)</sup>. Therefore, infant tolerance cannot be assumed to be a basis for adult
tolerance, and therefore doses lower than the potential maximum infant exposure were
selected. To assess the adult tolerance of daily boluses of 2&#x02032;FL and LNnT, the participants
were asked to fill in a GSRS questionnaire. At entry, the mean score on the GSRS total was
less than the population norm of 1&#x000b7;53 based on a Swedish adult background population<sup>(</sup>
<xref rid="ref59" ref-type="bibr">
<sup>59</sup>
</xref>
<sup>)</sup>. The mean scores on the GSRS total after intervention remained below the
population norm except for the group receiving the 20-g dose of 2&#x02032;FL. This increased to
1&#x000b7;87, which is still rated as minor discomfort on the GSRS scale. For individual symptoms,
an increase in passing gas and bloating was observed for the higher doses of 2&#x02032;FL and LNnT
alone. However, even these scores remained low during the intervention and were rated as
mild discomfort on the GSRS scale. Therefore, we conclude that 2&#x02032;FL, LNnT and a mix of 2&#x02032;FL
and LNnT are well tolerated by healthy adults even at high bolus doses. Interestingly, none
of the doses of the mix of 2&#x02032;FL and LNnT induced GI symptoms as measured by the GSRS. The
tolerance conclusions based on the GSRS scores are corroborated by the stool frequency and
stool consistency results, which revealed at most small, clinically irrelevant changes.</p><p>A main objective of this study was to assess the effect of 2&#x02032;FL and LNnT on the adult gut
microbiota. Several studies have examined the impact of prebiotics such as
galacto-oligosaccharides and fructo-oligosaccharides on the human intestinal microbiota,
although most studies only monitored a few selected bacterial taxa using qPCR or
fluorescence <italic>in situ</italic> hybridisation<sup>(</sup>
<xref rid="ref60" ref-type="bibr">
<sup>60</sup>
</xref>
<sup>&#x02013;</sup>
<xref rid="ref62" ref-type="bibr">
<sup>62</sup>
</xref>
<sup>)</sup>. Only a few studies provided comprehensive, high-resolution data of the human
gut microbiota through high-throughput sequencing, after prebiotic consumption<sup>(</sup>
<xref rid="ref63" ref-type="bibr">
<sup>63</sup>
</xref>
<sup>,</sup>
<xref rid="ref64" ref-type="bibr">
<sup>64</sup>
</xref>
<sup>)</sup>.</p><p>Our study showed that the uptake of 2&#x02032;FL and LNnT for 2 weeks is sufficient to modulate the
adult microbiota. An increase in relative abundance of bifidobacteria, to &#x0003e;25 % in
some individuals, and a reduction in relative abundance of two phyla, Firmicutes and
Proteobacteria, were observed. This modulation occurred rapidly &#x02013; namely, within 1&#x02013;2 weeks &#x02013;
and the bifidogenic effect was significant despite being on top of a normal,
non-standardised complex adult diet. The observed increase in bifidobacteria was dose
dependent but unrelated to the initial bifidobacteria abundance. Different results have been
observed for galacto-oligosaccharides, where the greatest bifidogenic response occurred in
individuals having the highest initial bifidobacteria abundance<sup>(</sup>
<xref rid="ref61" ref-type="bibr">
<sup>61</sup>
</xref>
<sup>)</sup>.</p><p>Interestingly, most of the increase in bifidobacteria abundance can be explained by the
increase in a specific OTU (s1_r64). This OTU has high sequence similarity (&#x0003e;99 %) to
<italic>B. adolescentis</italic>, which is surprising, given that <italic>B.
adolescentis</italic> is not known to metabolise HMO<sup>(</sup>
<xref rid="ref65" ref-type="bibr">
<sup>65</sup>
</xref>
<sup>)</sup>. However, based on the 16S rRNA sequencing data, we cannot exclude at this
stage that the OTU is in fact another member of <italic>Bifidobacterium</italic>. To assess
the impact of 2&#x02032;FL and LNnT supplementation on other genera relevant to human health, we
specifically looked at changes in the relative abundance of eighteen genera reported to be
correlated to health or disease in conditions such as obesity, irritable bowel syndrome or
inflammatory bowel disease<sup>(</sup>
<xref rid="ref55" ref-type="bibr">
<sup>55</sup>
</xref>
<sup>&#x02013;</sup>
<xref rid="ref57" ref-type="bibr">
<sup>57</sup>
</xref>
<sup>)</sup>. The abundance of putative beneficial taxa such as
<italic>Faecalibacterium</italic>, <italic>Roseburia</italic>, <italic>Akkermansia</italic>
or <italic>Lactobacillus</italic>, however, did not decrease concomitantly to the increase
in bifidobacteria observed in 2&#x02032;FL- and LNnT-supplemented subjects.</p><p>Bifidobacteria have for long been regarded as beneficial members of the human gut
microbiota, and low levels have been reported in obese and diabetic individuals<sup>(</sup>
<xref rid="ref41" ref-type="bibr">
<sup>41</sup>
</xref>
<sup>,</sup>
<xref rid="ref66" ref-type="bibr">
<sup>66</sup>
</xref>
<sup>)</sup>, in individuals taking antibiotics<sup>(</sup>
<xref rid="ref67" ref-type="bibr">
<sup>67</sup>
</xref>
<sup>)</sup> and in patients suffering from irritable bowel syndrome or inflammatory bowel
disease<sup>(</sup>
<xref rid="ref39" ref-type="bibr">
<sup>39</sup>
</xref>
<sup>,</sup>
<xref rid="ref68" ref-type="bibr">
<sup>68</sup>
</xref>
<sup>)</sup>. Safe and well-tolerated interventions, such as HMO supplementation, thus
represent approaches worth considering to replenish bifidobacteria in individuals presenting
low levels of these bacteria.</p><p>In conclusion, we show that 2&#x02032;FL and LNnT are safe and well tolerated in healthy adults.
Intriguingly, the mix of 2&#x02032;FL and LNnT was better tolerated than the individual HMO when
given at high doses. We further show that both 2&#x02032;FL and LNnT are specific modulators of the
adult microbiota with a very specific increase in bifidobacteria, particularly one OTU
(s1_r64). Our results suggest that supplementing the diet with 2&#x02032;FL and LNnT may be a
valuable tool to restore homoeostasis in adults having an imbalanced microbiota.</p></sec></body><back><ack id="ack1"><title>Acknowledgements</title><p>The authors acknowledge Sacha Schneeberger and Luca Plan at the University of Zurich for
their assistance in the analysis of faecal biomarkers and Christoph Roehrig for excellent
scientific advice.</p><p>E. E., L. K. V. and B. M. planned the design and interpreted the results of the study and
prepared the manuscript. T. H., M. O. A. S. and P. B. took part in planning the design of
the study. P. B., L. R. K. and J. R. coordinated the execution of the study and monitored
the subjects during the trial. M. O. A. S. and N. S. performed microbiota profiling and
statistical analysis of these results. T. H. was responsible for the analysis of faecal
biomarkers. E. E., L. K. V., B. M., T. H., P. B., N. S. and M. O. A. S. contributed to the
final manuscript with intellectual and scientific input.</p><p>E. E., L. K. V. and B. M. are employed at Glycom A/S, Denmark, which funded this study. T.
H., M. O. A. S. and P. B. were paid consultants of Glycom A/S.</p></ack><sec sec-type="supplementary-material" id="sec4"><title>Supplementary material</title><supplementary-material content-type="local-data" id="S0007114516003354sup001"><p>For supplementary material accompanying this paper visit http://dx.doi.org/10.1017/S0007114516003354.</p><media xlink:href="S0007114516003354sup001.pdf" mimetype="application" mime-subtype="pdf" orientation="portrait" id="d36e2468" position="anchor"><caption><p>click here to view supplementary material</p></caption></media></supplementary-material></sec><ref-list id="refs"><title>References</title><ref id="ref1"><label>1.</label><mixed-citation publication-type="journal">
<name><surname>Nicholson</surname><given-names>JK</given-names></name>, <name><surname>Holmes</surname><given-names>E</given-names></name>, <name><surname>Kinross</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Host-gut microbiota
metabolic interactions</article-title>. <source>Science</source>
<volume>336</volume>, <fpage>1262</fpage>&#x02013;<lpage>1267</lpage>.<pub-id pub-id-type="pmid">22674330</pub-id></mixed-citation></ref><ref id="ref2"><label>2.</label><mixed-citation publication-type="journal">
<name><surname>Utzschneider</surname><given-names>KM</given-names></name>, <name><surname>Kratz</surname><given-names>M</given-names></name>, <name><surname>Damman</surname><given-names>CJ</given-names></name>, <etal>et al</etal> (<year>2016</year>) <article-title>Mechanisms linking the gut
microbiome and glucose metabolism</article-title>. <source>J Clin Endocrinol Metab</source>
<volume>101</volume>, <fpage>1445</fpage>&#x02013;<lpage>1454</lpage>.<pub-id pub-id-type="pmid">26938201</pub-id></mixed-citation></ref><ref id="ref3"><label>3.</label><mixed-citation publication-type="journal">
<name><surname>Wu</surname><given-names>HJ</given-names></name> &#x00026; <name><surname>Wu</surname><given-names>E</given-names></name> (<year>2012</year>) <article-title>The role of gut microbiota in immune
homeostasis and autoimmunity</article-title>. <source>Gut Microbes</source>
<volume>3</volume>, <fpage>4</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="pmid">22356853</pub-id></mixed-citation></ref><ref id="ref4"><label>4.</label><mixed-citation publication-type="journal">
<name><surname>Belkaid</surname><given-names>Y</given-names></name> &#x00026; <name><surname>Hand</surname><given-names>TW</given-names></name> (<year>2014</year>) <article-title>Role of the microbiota in immunity and
inflammation</article-title>. <source>Cell</source>
<volume>157</volume>, <fpage>121</fpage>&#x02013;<lpage>141</lpage>.<pub-id pub-id-type="pmid">24679531</pub-id></mixed-citation></ref><ref id="ref5"><label>5.</label><mixed-citation publication-type="journal">
<name><surname>Shi</surname><given-names>HN</given-names></name> &#x00026; <name><surname>Walker</surname><given-names>A</given-names></name> (<year>2004</year>) <article-title>Bacterial colonization and the development of
intestinal defences</article-title>. <source>Can J Gastroenterol</source>
<volume>18</volume>, <fpage>493</fpage>&#x02013;<lpage>500</lpage>.<pub-id pub-id-type="pmid">15372112</pub-id></mixed-citation></ref><ref id="ref6"><label>6.</label><mixed-citation publication-type="journal">
<name><surname>Le Chatelier</surname><given-names>E</given-names></name>, <name><surname>Nielsen</surname><given-names>T</given-names></name>, <name><surname>Qin</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Richness of human gut
microbiome correlates with metabolic markers</article-title>. <source>Nature</source>
<volume>500</volume>, <fpage>541</fpage>&#x02013;<lpage>546</lpage>.<pub-id pub-id-type="pmid">23985870</pub-id></mixed-citation></ref><ref id="ref7"><label>7.</label><mixed-citation publication-type="journal">
<name><surname>Turnbaugh</surname><given-names>PJ</given-names></name>, <name><surname>Hamady</surname><given-names>M</given-names></name>, <name><surname>Yatsunenko</surname><given-names>T</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>A core gut microbiome in
obese and lean twins</article-title>. <source>Nature</source>
<volume>457</volume>, <fpage>480</fpage>&#x02013;<lpage>484</lpage>.<pub-id pub-id-type="pmid">19043404</pub-id></mixed-citation></ref><ref id="ref8"><label>8.</label><mixed-citation publication-type="journal">
<name><surname>Qin</surname><given-names>N</given-names></name>, <name><surname>Yang</surname><given-names>F</given-names></name>, <name><surname>Li</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Alterations of the human
gut microbiome in liver cirrhosis</article-title>. <source>Nature</source>
<volume>513</volume>, <fpage>59</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="pmid">25079328</pub-id></mixed-citation></ref><ref id="ref9"><label>9.</label><mixed-citation publication-type="journal">
<name><surname>Brown</surname><given-names>JM</given-names></name> &#x00026; <name><surname>Hazen</surname><given-names>SL</given-names></name> (<year>2015</year>) <article-title>The gut microbial endocrine organ: bacterially
derived signals driving cardiometabolic diseases</article-title>. <source>Annu Rev Med</source>
<volume>66</volume>, <fpage>343</fpage>&#x02013;<lpage>359</lpage>.<pub-id pub-id-type="pmid">25587655</pub-id></mixed-citation></ref><ref id="ref10"><label>10.</label><mixed-citation publication-type="journal">
<name><surname>Karlsson</surname><given-names>FH</given-names></name>, <name><surname>Tremaroli</surname><given-names>V</given-names></name>, <name><surname>Nookaew</surname><given-names>I</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Gut metagenome in European
women with normal, impaired and diabetic glucose control</article-title>. <source>Nature</source>
<volume>498</volume>, <fpage>99</fpage>&#x02013;<lpage>103</lpage>.<pub-id pub-id-type="pmid">23719380</pub-id></mixed-citation></ref><ref id="ref11"><label>11.</label><mixed-citation publication-type="journal">
<name><surname>Qin</surname><given-names>J</given-names></name>, <name><surname>Li</surname><given-names>Y</given-names></name>, <name><surname>Cai</surname><given-names>Z</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>A metagenome-wide
association study of gut microbiota in type 2 diabetes</article-title>. <source>Nature</source>
<volume>490</volume>, <fpage>55</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">23023125</pub-id></mixed-citation></ref><ref id="ref12"><label>12.</label><mixed-citation publication-type="journal">
<name><surname>Palm</surname><given-names>NW</given-names></name>, <name><surname>de Zoete</surname><given-names>MR</given-names></name>, <name><surname>Cullen</surname><given-names>TW</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Immunoglobulin A coating
identifies colitogenic bacteria in inflammatory bowel disease</article-title>.
<source>Cell</source>
<volume>158</volume>, <fpage>1000</fpage>&#x02013;<lpage>1010</lpage>.<pub-id pub-id-type="pmid">25171403</pub-id></mixed-citation></ref><ref id="ref13"><label>13.</label><mixed-citation publication-type="journal">
<name><surname>Zackular</surname><given-names>JP</given-names></name>, <name><surname>Rogers</surname><given-names>MA</given-names></name>, <name><surname>Ruffin</surname><given-names>MTt</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>The human gut microbiome
as a screening tool for colorectal cancer</article-title>. <source>Cancer Prev Res
(Phila)</source>
<volume>7</volume>, <fpage>1112</fpage>&#x02013;<lpage>1121</lpage>.<pub-id pub-id-type="pmid">25104642</pub-id></mixed-citation></ref><ref id="ref14"><label>14.</label><mixed-citation publication-type="journal">
<name><surname>Fujimura</surname><given-names>KE</given-names></name>, <name><surname>Slusher</surname><given-names>NA</given-names></name>, <name><surname>Cabana</surname><given-names>MD</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Role of the gut microbiota
in defining human health</article-title>. <source>Expert Rev Anti Infect Ther</source>
<volume>8</volume>, <fpage>435</fpage>&#x02013;<lpage>454</lpage>.<pub-id pub-id-type="pmid">20377338</pub-id></mixed-citation></ref><ref id="ref15"><label>15.</label><mixed-citation publication-type="journal">
<name><surname>van Nood</surname><given-names>E</given-names></name>, <name><surname>Vrieze</surname><given-names>A</given-names></name>, <name><surname>Nieuwdorp</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Duodenal infusion of donor
feces for recurrent <italic>Clostridium difficile</italic>
</article-title>. <source>N Engl J Med</source>
<volume>368</volume>, <fpage>407</fpage>&#x02013;<lpage>415</lpage>.<pub-id pub-id-type="pmid">23323867</pub-id></mixed-citation></ref><ref id="ref16"><label>16.</label><mixed-citation publication-type="journal">
<name><surname>Ballard</surname><given-names>O</given-names></name> &#x00026; <name><surname>Morrow</surname><given-names>AL</given-names></name> (<year>2013</year>) <article-title>Human milk composition: nutrients and bioactive
factors</article-title>. <source>Pediatr Clin North Am</source>
<volume>60</volume>, <fpage>49</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">23178060</pub-id></mixed-citation></ref><ref id="ref17"><label>17.</label><mixed-citation publication-type="journal">
<name><surname>Bezirtzoglou</surname><given-names>E</given-names></name>, <name><surname>Tsiotsias</surname><given-names>A</given-names></name> &#x00026; <name><surname>Welling</surname><given-names>GW</given-names></name> (<year>2011</year>) <article-title>Microbiota profile in feces of breast- and
formula-fed newborns by using fluorescence in situ hybridization (FISH)</article-title>.
<source>Anaerobe</source>
<volume>17</volume>, <fpage>478</fpage>&#x02013;<lpage>482</lpage>.<pub-id pub-id-type="pmid">21497661</pub-id></mixed-citation></ref><ref id="ref18"><label>18.</label><mixed-citation publication-type="journal">
<name><surname>Gabrielli</surname><given-names>O</given-names></name>, <name><surname>Zampini</surname><given-names>L</given-names></name>, <name><surname>Galeazzi</surname><given-names>T</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Preterm milk
oligosaccharides during the first month of lactation</article-title>. <source>Pediatrics</source>
<volume>128</volume>, <fpage>e1520</fpage>&#x02013;<lpage>e1531</lpage>.<pub-id pub-id-type="pmid">22123889</pub-id></mixed-citation></ref><ref id="ref19"><label>19.</label><mixed-citation publication-type="journal">
<name><surname>ten Bruggencate</surname><given-names>SJ</given-names></name>, <name><surname>Bovee-Oudenhoven</surname><given-names>IM</given-names></name>, <name><surname>Feitsma</surname><given-names>AL</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Functional role and
mechanisms of sialyllactose and other sialylated milk oligosaccharides</article-title>.
<source>Nutr Rev</source>
<volume>72</volume>, <fpage>377</fpage>&#x02013;<lpage>389</lpage>.<pub-id pub-id-type="pmid">24828428</pub-id></mixed-citation></ref><ref id="ref20"><label>20.</label><mixed-citation publication-type="journal">
<name><surname>Rudloff</surname><given-names>S</given-names></name>, <name><surname>Obermeier</surname><given-names>S</given-names></name>, <name><surname>Borsch</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Incorporation of orally
applied (13)C-galactose into milk lactose and oligosaccharides</article-title>.
<source>Glycobiology</source>
<volume>16</volume>, <fpage>477</fpage>&#x02013;<lpage>487</lpage>.<pub-id pub-id-type="pmid">16495330</pub-id></mixed-citation></ref><ref id="ref21"><label>21.</label><mixed-citation publication-type="journal">
<name><surname>Garrido</surname><given-names>D</given-names></name>, <name><surname>Dallas</surname><given-names>DC</given-names></name> &#x00026; <name><surname>Mills</surname><given-names>DA</given-names></name> (<year>2013</year>) <article-title>Consumption of human milk glycoconjugates by
infant-associated bifidobacteria: mechanisms and implications</article-title>.
<source>Microbiology</source>
<volume>159</volume>, <fpage>649</fpage>&#x02013;<lpage>664</lpage>.<pub-id pub-id-type="pmid">23460033</pub-id></mixed-citation></ref><ref id="ref22"><label>22.</label><mixed-citation publication-type="journal">
<name><surname>Ruiz-Moyano</surname><given-names>S</given-names></name>, <name><surname>Totten</surname><given-names>SM</given-names></name>, <name><surname>Garrido</surname><given-names>DA</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Variation in consumption
of human milk oligosaccharides by infant gut-associated strains of
<italic>Bifidobacterium breve</italic>
</article-title>. <source>Appl Environ Microbiol</source>
<volume>79</volume>, <fpage>6040</fpage>&#x02013;<lpage>6049</lpage>.<pub-id pub-id-type="pmid">23892749</pub-id></mixed-citation></ref><ref id="ref23"><label>23.</label><mixed-citation publication-type="journal">
<name><surname>Yu</surname><given-names>ZT</given-names></name>, <name><surname>Chen</surname><given-names>C</given-names></name>, <name><surname>Kling</surname><given-names>DE</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>The principal fucosylated
oligosaccharides of human milk exhibit prebiotic properties on cultured infant
microbiota</article-title>. <source>Glycobiology</source>
<volume>23</volume>, <fpage>169</fpage>&#x02013;<lpage>177</lpage>.<pub-id pub-id-type="pmid">23028202</pub-id></mixed-citation></ref><ref id="ref24"><label>24.</label><mixed-citation publication-type="journal">
<name><surname>Yu</surname><given-names>ZT</given-names></name>, <name><surname>Chen</surname><given-names>C</given-names></name> &#x00026; <name><surname>Newburg</surname><given-names>DS</given-names></name> (<year>2013</year>) <article-title>Utilization of major fucosylated and sialylated
human milk oligosaccharides by isolated human gut microbes</article-title>.
<source>Glycobiology</source>
<volume>23</volume>, <fpage>1281</fpage>&#x02013;<lpage>1292</lpage>.<pub-id pub-id-type="pmid">24013960</pub-id></mixed-citation></ref><ref id="ref25"><label>25.</label><mixed-citation publication-type="journal">
<name><surname>Marcobal</surname><given-names>A</given-names></name>, <name><surname>Barboza</surname><given-names>M</given-names></name>, <name><surname>Froehlich</surname><given-names>JW</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Consumption of human milk
oligosaccharides by gut-related microbes</article-title>. <source>J Agric Food Chem</source>
<volume>58</volume>, <fpage>5334</fpage>&#x02013;<lpage>5340</lpage>.<pub-id pub-id-type="pmid">20394371</pub-id></mixed-citation></ref><ref id="ref26"><label>26.</label><mixed-citation publication-type="journal">
<name><surname>Marcobal</surname><given-names>A</given-names></name> &#x00026; <name><surname>Sonnenburg</surname><given-names>JL</given-names></name> (<year>2012</year>) <article-title>Human milk oligosaccharide consumption by
intestinal microbiota</article-title>. <source>Clin Microbiol Infect</source>
<volume>18</volume>, <issue>Suppl. 4</issue>,
<fpage>12</fpage>&#x02013;<lpage>15</lpage>.<pub-id pub-id-type="pmid">22647041</pub-id></mixed-citation></ref><ref id="ref27"><label>27.</label><mixed-citation publication-type="journal">
<name><surname>Ward</surname><given-names>RE</given-names></name>, <name><surname>Ninonuevo</surname><given-names>M</given-names></name>, <name><surname>Mills</surname><given-names>DA</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>
<italic>In vitro</italic> fermentability of human milk oligosaccharides by several
strains of bifidobacteria</article-title>. <source>Mol Nutr Food Res</source>
<volume>51</volume>, <fpage>1398</fpage>&#x02013;<lpage>1405</lpage>.<pub-id pub-id-type="pmid">17966141</pub-id></mixed-citation></ref><ref id="ref28"><label>28.</label><mixed-citation publication-type="journal">
<name><surname>Bode</surname><given-names>L</given-names></name>, <name><surname>Kunz</surname><given-names>C</given-names></name>, <name><surname>Muhly-Reinholz</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>Inhibition of monocyte,
lymphocyte, and neutrophil adhesion to endothelial cells by human milk
oligosaccharides</article-title>. <source>Thromb Haemost</source>
<volume>92</volume>, <fpage>1402</fpage>&#x02013;<lpage>1410</lpage>.<pub-id pub-id-type="pmid">15583750</pub-id></mixed-citation></ref><ref id="ref29"><label>29.</label><mixed-citation publication-type="journal">
<name><surname>Bode</surname><given-names>L</given-names></name>, <name><surname>Rudloff</surname><given-names>S</given-names></name>, <name><surname>Kunz</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>Human milk
oligosaccharides reduce platelet-neutrophil complex formation leading to a decrease in
neutrophil beta 2 integrin expression</article-title>. <source>J Leukoc Biol</source>
<volume>76</volume>, <fpage>820</fpage>&#x02013;<lpage>826</lpage>.<pub-id pub-id-type="pmid">15240751</pub-id></mixed-citation></ref><ref id="ref30"><label>30.</label><mixed-citation publication-type="journal">
<name><surname>Comstock</surname><given-names>SS</given-names></name>, <name><surname>Wang</surname><given-names>M</given-names></name>, <name><surname>Hester</surname><given-names>SN</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Select human milk
oligosaccharides directly modulate peripheral blood mononuclear cells isolated from
10-d-old pigs</article-title>. <source>Br J Nutr</source>
<volume>111</volume>, <fpage>819</fpage>&#x02013;<lpage>828</lpage>.<pub-id pub-id-type="pmid">24131853</pub-id></mixed-citation></ref><ref id="ref31"><label>31.</label><mixed-citation publication-type="journal">
<name><surname>Newburg</surname><given-names>DS</given-names></name>, <name><surname>Tanritanir</surname><given-names>AC</given-names></name> &#x00026; <name><surname>Chakrabarti</surname><given-names>S</given-names></name> (<year>2016</year>) <article-title>Lactodifucotetraose, a human milk
oligosaccharide, attenuates platelet function and inflammatory cytokine
release</article-title>. <source>J Thromb Thrombolysis</source>
<volume>42</volume>, <fpage>46</fpage>&#x02013;<lpage>55</lpage>.<pub-id pub-id-type="pmid">26743063</pub-id></mixed-citation></ref><ref id="ref32"><label>32.</label><mixed-citation publication-type="journal">
<name><surname>Coppa</surname><given-names>GV</given-names></name>, <name><surname>Zampini</surname><given-names>L</given-names></name>, <name><surname>Galeazzi</surname><given-names>T</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Human milk
oligosaccharides inhibit the adhesion to Caco-2 cells of diarrheal pathogens:
<italic>Escherichia coli</italic>, <italic>Vibrio cholerae</italic>, and
<italic>Salmonella fyris</italic>
</article-title>. <source>Pediatr Res</source>
<volume>59</volume>, <fpage>377</fpage>&#x02013;<lpage>382</lpage>.<pub-id pub-id-type="pmid">16492975</pub-id></mixed-citation></ref><ref id="ref33"><label>33.</label><mixed-citation publication-type="journal">
<name><surname>Hester</surname><given-names>SN</given-names></name>, <name><surname>Chen</surname><given-names>X</given-names></name>, <name><surname>Li</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Human milk
oligosaccharides inhibit rotavirus infectivity <italic>in vitro</italic> and in acutely
infected piglets</article-title>. <source>Br J Nutr</source>
<volume>110</volume>, <fpage>1233</fpage>&#x02013;<lpage>1242</lpage>.<pub-id pub-id-type="pmid">23442265</pub-id></mixed-citation></ref><ref id="ref34"><label>34.</label><mixed-citation publication-type="journal">
<name><surname>Morrow</surname><given-names>AL</given-names></name>, <name><surname>Ruiz-Palacios</surname><given-names>GM</given-names></name>, <name><surname>Jiang</surname><given-names>X</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Human-milk glycans that
inhibit pathogen binding protect breast-feeding infants against infectious
diarrhea</article-title>. <source>J Nutr</source>
<volume>135</volume>, <fpage>1304</fpage>&#x02013;<lpage>1307</lpage>.<pub-id pub-id-type="pmid">15867329</pub-id></mixed-citation></ref><ref id="ref35"><label>35.</label><mixed-citation publication-type="journal">
<name><surname>Newburg</surname><given-names>DS</given-names></name>, <name><surname>Ruiz-Palacios</surname><given-names>GM</given-names></name> &#x00026; <name><surname>Morrow</surname><given-names>AL</given-names></name> (<year>2005</year>) <article-title>Human milk glycans protect infants against
enteric pathogens</article-title>. <source>Annu Rev Nutr</source>
<volume>25</volume>, <fpage>37</fpage>&#x02013;<lpage>58</lpage>.<pub-id pub-id-type="pmid">16011458</pub-id></mixed-citation></ref><ref id="ref36"><label>36.</label><mixed-citation publication-type="journal">
<name><surname>Newburg</surname><given-names>DS</given-names></name>, <name><surname>Ruiz-Palacios</surname><given-names>GM</given-names></name>, <name><surname>Altaye</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>Innate protection
conferred by fucosylated oligosaccharides of human milk against diarrhea in breastfed
infants</article-title>. <source>Glycobiology</source>
<volume>14</volume>, <fpage>253</fpage>&#x02013;<lpage>263</lpage>.<pub-id pub-id-type="pmid">14638628</pub-id></mixed-citation></ref><ref id="ref37"><label>37.</label><mixed-citation publication-type="journal">
<name><surname>Turroni</surname><given-names>F</given-names></name>, <name><surname>Peano</surname><given-names>C</given-names></name>, <name><surname>Pass</surname><given-names>DA</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Diversity of
bifidobacteria within the infant gut microbiota</article-title>. <source>PLOS ONE</source>
<volume>7</volume>, <fpage>e36957</fpage>.<pub-id pub-id-type="pmid">22606315</pub-id></mixed-citation></ref><ref id="ref38"><label>38.</label><mixed-citation publication-type="journal">
<name><surname>Sela</surname><given-names>DA</given-names></name> &#x00026; <name><surname>Mills</surname><given-names>DA</given-names></name> (<year>2010</year>) <article-title>Nursing our microbiota: molecular linkages
between bifidobacteria and milk oligosaccharides</article-title>. <source>Trends
Microbiol</source>
<volume>18</volume>, <fpage>298</fpage>&#x02013;<lpage>307</lpage>.<pub-id pub-id-type="pmid">20409714</pub-id></mixed-citation></ref><ref id="ref39"><label>39.</label><mixed-citation publication-type="journal">
<name><surname>Kerckhoffs</surname><given-names>AP</given-names></name>, <name><surname>Samsom</surname><given-names>M</given-names></name>, <name><surname>van der Rest</surname><given-names>ME</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Lower bifidobacteria
counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel
syndrome patients</article-title>. <source>World J Gastroenterol</source>
<volume>15</volume>, <fpage>2887</fpage>&#x02013;<lpage>2892</lpage>.<pub-id pub-id-type="pmid">19533811</pub-id></mixed-citation></ref><ref id="ref40"><label>40.</label><mixed-citation publication-type="journal">
<name><surname>Parkes</surname><given-names>GC</given-names></name>, <name><surname>Rayment</surname><given-names>NB</given-names></name>, <name><surname>Hudspith</surname><given-names>BN</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Distinct microbial
populations exist in the mucosa-associated microbiota of sub-groups of irritable bowel
syndrome</article-title>. <source>Neurogastroenterol Motil</source>
<volume>24</volume>, <fpage>31</fpage>&#x02013;<lpage>39</lpage>.<pub-id pub-id-type="pmid">22070725</pub-id></mixed-citation></ref><ref id="ref41"><label>41.</label><mixed-citation publication-type="journal">
<name><surname>Schwiertz</surname><given-names>A</given-names></name>, <name><surname>Taras</surname><given-names>D</given-names></name>, <name><surname>Schafer</surname><given-names>K</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Microbiota and SCFA in
lean and overweight healthy subjects</article-title>. <source>Obesity (Silver Spring)</source>
<volume>18</volume>, <fpage>190</fpage>&#x02013;<lpage>195</lpage>.<pub-id pub-id-type="pmid">19498350</pub-id></mixed-citation></ref><ref id="ref42"><label>42.</label><mixed-citation publication-type="journal">
<name><surname>Le</surname><given-names>KA</given-names></name>, <name><surname>Li</surname><given-names>Y</given-names></name>, <name><surname>Xu</surname><given-names>X</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Alterations in fecal
<italic>Lactobacillus</italic> and <italic>Bifidobacterium</italic> species in type 2
diabetic patients in Southern China population</article-title>. <source>Front Physiol</source>
<volume>3</volume>, <fpage>496</fpage>.<pub-id pub-id-type="pmid">23386831</pub-id></mixed-citation></ref><ref id="ref43"><label>43.</label><mixed-citation publication-type="journal">
<name><surname>Ouwehand</surname><given-names>AC</given-names></name>, <name><surname>Salminen</surname><given-names>S</given-names></name> &#x00026; <name><surname>Isolauri</surname><given-names>E</given-names></name> (<year>2002</year>) <article-title>Probiotics: an overview of beneficial
effects</article-title>. <source>Antonie van Leeuwenhoek</source>
<volume>82</volume>, <fpage>279</fpage>&#x02013;<lpage>289</lpage>.<pub-id pub-id-type="pmid">12369194</pub-id></mixed-citation></ref><ref id="ref44"><label>44.</label><mixed-citation publication-type="journal">
<name><surname>Coulet</surname><given-names>M</given-names></name>, <name><surname>Phothirath</surname><given-names>P</given-names></name>, <name><surname>Allais</surname><given-names>L</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Pre-clinical safety
evaluation of the synthetic human milk, nature-identical, oligosaccharide
2&#x02019;-O-Fucosyllactose (2&#x02019;FL)</article-title>. <source>Regul Toxicol Pharmacol</source>
<volume>68</volume>, <fpage>59</fpage>&#x02013;<lpage>69</lpage>.<pub-id pub-id-type="pmid">24262411</pub-id></mixed-citation></ref><ref id="ref45"><label>45.</label><mixed-citation publication-type="journal">
<name><surname>Coulet</surname><given-names>M</given-names></name>, <name><surname>Phothirath</surname><given-names>P</given-names></name>, <name><surname>Constable</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Pre-clinical safety
assessment of the synthetic human milk, nature-identical, oligosaccharide
Lacto-N-neotetraose (LNnT)</article-title>. <source>Food Chem Toxicol</source>
<volume>62</volume>, <fpage>528</fpage>&#x02013;<lpage>537</lpage>.<pub-id pub-id-type="pmid">24071476</pub-id></mixed-citation></ref><ref id="ref46"><label>46.</label><mixed-citation publication-type="journal">
<collab>EFSA Panel on Dietetic Products Nutrition and Allergies</collab>
(<year>2015</year>) <article-title>Safety of 2&#x02019;-O-fucosyllactose as a novel food
ingredient pursuant to Regulation (EC) No 258/97</article-title>. <source>EFSA J</source>
<volume>13</volume>, <fpage>4184</fpage>.</mixed-citation></ref><ref id="ref47"><label>47.</label><mixed-citation publication-type="journal">
<collab>EFSA Panel on Dietetic Products Nutrition and Allergies</collab>
(<year>2015</year>) <article-title>Safety of lacto-N-neotetraose as a novel food
ingredient pursuant to Regulation (EC) No 258/97</article-title>. <source>EFSA J</source>
<volume>13</volume>, <fpage>4183</fpage>.</mixed-citation></ref><ref id="ref48"><label>48.</label><mixed-citation publication-type="journal">
<name><surname>Dimenas</surname><given-names>E</given-names></name>, <name><surname>Glise</surname><given-names>H</given-names></name>, <name><surname>Hallerback</surname><given-names>B</given-names></name>, <etal>et al</etal> (<year>1995</year>) <article-title>Well-being and
gastrointestinal symptoms among patients referred to endoscopy owing to suspected
duodenal ulcer</article-title>. <source>Scand J Gastroenterol</source>
<volume>30</volume>, <fpage>1046</fpage>&#x02013;<lpage>1052</lpage>.<pub-id pub-id-type="pmid">8578162</pub-id></mixed-citation></ref><ref id="ref49"><label>49.</label><mixed-citation publication-type="journal">
<name><surname>Lewis</surname><given-names>SJ</given-names></name> &#x00026; <name><surname>Heaton</surname><given-names>KW</given-names></name> (<year>1997</year>) <article-title>Stool form scale as a useful guide to
intestinal transit time</article-title>. <source>Scand J Gastroenterol</source>
<volume>32</volume>, <fpage>920</fpage>&#x02013;<lpage>924</lpage>.<pub-id pub-id-type="pmid">9299672</pub-id></mixed-citation></ref><ref id="ref50"><label>50.</label><mixed-citation publication-type="journal">
<name><surname>Klindworth</surname><given-names>A</given-names></name>, <name><surname>Pruesse</surname><given-names>E</given-names></name>, <name><surname>Schweer</surname><given-names>T</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Evaluation of general 16S
ribosomal RNA gene PCR primers for classical and next-generation sequencing-based
diversity studies</article-title>. <source>Nucleic Acids Res</source>
<volume>41</volume>, <fpage>e1</fpage>.<pub-id pub-id-type="pmid">22933715</pub-id></mixed-citation></ref><ref id="ref51"><label>51.</label><mixed-citation publication-type="journal">
<name><surname>Edgar</surname><given-names>RC</given-names></name> (<year>2013</year>) <article-title>UPARSE: highly accurate OTU sequences from
microbial amplicon reads</article-title>. <source>Nat Methods</source>
<volume>10</volume>, <fpage>996</fpage>&#x02013;<lpage>998</lpage>.<pub-id pub-id-type="pmid">23955772</pub-id></mixed-citation></ref><ref id="ref52"><label>52.</label><mixed-citation publication-type="journal">
<name><surname>Edgar</surname><given-names>RC</given-names></name>, <name><surname>Haas</surname><given-names>BJ</given-names></name>, <name><surname>Clemente</surname><given-names>JC</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>UCHIME improves
sensitivity and speed of chimera detection</article-title>. <source>Bioinformatics</source>
<volume>27</volume>, <fpage>2194</fpage>&#x02013;<lpage>2200</lpage>.<pub-id pub-id-type="pmid">21700674</pub-id></mixed-citation></ref><ref id="ref53"><label>53.</label><mixed-citation publication-type="journal">
<name><surname>Cole</surname><given-names>JR</given-names></name>, <name><surname>Wang</surname><given-names>Q</given-names></name>, <name><surname>Fish</surname><given-names>JA</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Ribosomal Database
Project: data and tools for high throughput rRNA analysis</article-title>.
<source>Nucleic Acids Res</source>
<volume>42</volume>, <fpage>D633</fpage>&#x02013;<lpage>D642</lpage>.<pub-id pub-id-type="pmid">24288368</pub-id></mixed-citation></ref><ref id="ref54"><label>54.</label><mixed-citation publication-type="journal">
<name><surname>Chen</surname><given-names>J</given-names></name>, <name><surname>Bittinger</surname><given-names>K</given-names></name>, <name><surname>Charlson</surname><given-names>ES</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Associating microbiome
composition with environmental covariates using generalized UniFrac
distances</article-title>. <source>Bioinformatics</source>
<volume>28</volume>, <fpage>2106</fpage>&#x02013;<lpage>2113</lpage>.<pub-id pub-id-type="pmid">22711789</pub-id></mixed-citation></ref><ref id="ref55"><label>55.</label><mixed-citation publication-type="journal">
<name><surname>Casen</surname><given-names>C</given-names></name>, <name><surname>Vebo</surname><given-names>HC</given-names></name>, <name><surname>Sekelja</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2015</year>) <article-title>Deviations in human gut
microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or
IBD</article-title>. <source>Aliment Pharmacol Ther</source>
<volume>42</volume>, <fpage>71</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="pmid">25973666</pub-id></mixed-citation></ref><ref id="ref56"><label>56.</label><mixed-citation publication-type="journal">
<name><surname>Jeffery</surname><given-names>IB</given-names></name>, <name><surname>O&#x02019;Toole</surname><given-names>PW</given-names></name>, <name><surname>Ohman</surname><given-names>L</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>An irritable bowel
syndrome subtype defined by species-specific alterations in faecal
microbiota</article-title>. <source>Gut</source>
<volume>61</volume>, <fpage>997</fpage>&#x02013;<lpage>1006</lpage>.<pub-id pub-id-type="pmid">22180058</pub-id></mixed-citation></ref><ref id="ref57"><label>57.</label><mixed-citation publication-type="journal">
<name><surname>Walters</surname><given-names>WA</given-names></name>, <name><surname>Xu</surname><given-names>Z</given-names></name> &#x00026; <name><surname>Knight</surname><given-names>R</given-names></name> (<year>2014</year>) <article-title>Meta-analyses of human gut microbes associated
with obesity and IBD</article-title>. <source>FEBS Lett</source>
<volume>588</volume>, <fpage>4223</fpage>&#x02013;<lpage>4233</lpage>.<pub-id pub-id-type="pmid">25307765</pub-id></mixed-citation></ref><ref id="ref58"><label>58.</label><mixed-citation publication-type="journal">
<name><surname>Ten Bruggencate</surname><given-names>SJ</given-names></name>, <name><surname>Bovee-Oudenhoven</surname><given-names>IM</given-names></name>, <name><surname>Lettink-Wissink</surname><given-names>ML</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Dietary
fructooligosaccharides affect intestinal barrier function in healthy
men</article-title>. <source>J Nutr</source>
<volume>136</volume>, <fpage>70</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">16365061</pub-id></mixed-citation></ref><ref id="ref59"><label>59.</label><mixed-citation publication-type="journal">
<name><surname>Dimenas</surname><given-names>E</given-names></name>, <name><surname>Carlsson</surname><given-names>G</given-names></name>, <name><surname>Glise</surname><given-names>H</given-names></name>, <etal>et al</etal> (<year>1996</year>) <article-title>Relevance of norm values
as part of the documentation of quality of life instruments for use in upper
gastrointestinal disease</article-title>. <source>Scand J Gastroenterol</source>
<volume>221</volume>, <fpage>8</fpage>&#x02013;<lpage>13</lpage>.</mixed-citation></ref><ref id="ref60"><label>60.</label><mixed-citation publication-type="journal">
<name><surname>Costabile</surname><given-names>A</given-names></name>, <name><surname>Kolida</surname><given-names>S</given-names></name>, <name><surname>Klinder</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>A double-blind,
placebo-controlled, cross-over study to establish the bifidogenic effect of a
very-long-chain inulin extracted from globe artichoke (<italic>Cynara scolymus</italic>)
in healthy human subjects</article-title>. <source>Br J Nutr</source>
<volume>104</volume>, <fpage>1007</fpage>&#x02013;<lpage>1017</lpage>.<pub-id pub-id-type="pmid">20591206</pub-id></mixed-citation></ref><ref id="ref61"><label>61.</label><mixed-citation publication-type="journal">
<name><surname>Davis</surname><given-names>LM</given-names></name>, <name><surname>Martinez</surname><given-names>I</given-names></name>, <name><surname>Walter</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>A dose dependent impact of
prebiotic galactooligosaccharides on the intestinal microbiota of healthy
adults</article-title>. <source>Int J Food Microbiol</source>
<volume>144</volume>, <fpage>285</fpage>&#x02013;<lpage>292</lpage>.<pub-id pub-id-type="pmid">21059476</pub-id></mixed-citation></ref><ref id="ref62"><label>62.</label><mixed-citation publication-type="journal">
<name><surname>Vulevic</surname><given-names>J</given-names></name>, <name><surname>Drakoularakou</surname><given-names>A</given-names></name>, <name><surname>Yaqoob</surname><given-names>P</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Modulation of the fecal
microflora profile and immune function by a novel trans-galactooligosaccharide mixture
(B-GOS) in healthy elderly volunteers</article-title>. <source>Am J Clin Nutr</source>
<volume>88</volume>, <fpage>1438</fpage>&#x02013;<lpage>1446</lpage>.<pub-id pub-id-type="pmid">18996881</pub-id></mixed-citation></ref><ref id="ref63"><label>63.</label><mixed-citation publication-type="journal">
<name><surname>Davis</surname><given-names>LM</given-names></name>, <name><surname>Martinez</surname><given-names>I</given-names></name>, <name><surname>Walter</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Barcoded pyrosequencing
reveals that consumption of galactooligosaccharides results in a highly specific
bifidogenic response in humans</article-title>. <source>PLoS ONE</source>
<volume>6</volume>, <fpage>e25200</fpage>.<pub-id pub-id-type="pmid">21966454</pub-id></mixed-citation></ref><ref id="ref64"><label>64.</label><mixed-citation publication-type="journal">
<name><surname>Finegold</surname><given-names>SM</given-names></name>, <name><surname>Li</surname><given-names>Z</given-names></name>, <name><surname>Summanen</surname><given-names>PH</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Xylooligosaccharide
increases bifidobacteria but not lactobacilli in human gut microbiota</article-title>.
<source>Food Funct</source>
<volume>5</volume>, <fpage>436</fpage>&#x02013;<lpage>445</lpage>.<pub-id pub-id-type="pmid">24513849</pub-id></mixed-citation></ref><ref id="ref65"><label>65.</label><mixed-citation publication-type="journal">
<name><surname>Duranti</surname><given-names>S</given-names></name>, <name><surname>Turroni</surname><given-names>F</given-names></name>, <name><surname>Lugli</surname><given-names>GA</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Genomic characterization
and transcriptional studies of the starch-utilizing strain <italic>Bifidobacterium
adolescentis</italic> 22L</article-title>. <source>Appl Environ Microbiol</source>
<volume>80</volume>, <fpage>6080</fpage>&#x02013;<lpage>6090</lpage>.<pub-id pub-id-type="pmid">25063659</pub-id></mixed-citation></ref><ref id="ref66"><label>66.</label><mixed-citation publication-type="journal">
<name><surname>Duncan</surname><given-names>SH</given-names></name>, <name><surname>Lobley</surname><given-names>GE</given-names></name>, <name><surname>Holtrop</surname><given-names>G</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Human colonic microbiota
associated with diet, obesity and weight loss</article-title>. <source>Int J Obes (Lond)</source>
<volume>32</volume>, <fpage>1720</fpage>&#x02013;<lpage>1724</lpage>.<pub-id pub-id-type="pmid">18779823</pub-id></mixed-citation></ref><ref id="ref67"><label>67.</label><mixed-citation publication-type="journal">
<name><surname>Mangin</surname><given-names>I</given-names></name>, <name><surname>Leveque</surname><given-names>C</given-names></name>, <name><surname>Magne</surname><given-names>F</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Long-term changes in human
colonic <italic>Bifidobacterium</italic> populations induced by a 5-day oral
amoxicillin-clavulanic acid treatment</article-title>. <source>PLOS ONE</source>
<volume>7</volume>, <fpage>e50257</fpage>.<pub-id pub-id-type="pmid">23209691</pub-id></mixed-citation></ref><ref id="ref68"><label>68.</label><mixed-citation publication-type="journal">
<name><surname>Sokol</surname><given-names>H</given-names></name>, <name><surname>Seksik</surname><given-names>P</given-names></name>, <name><surname>Furet</surname><given-names>JP</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Low counts of
<italic>Faecalibacterium prausnitzii</italic> in colitis microbiota</article-title>.
<source>Inflamm Bowel Dis</source>
<volume>15</volume>, <fpage>1183</fpage>&#x02013;<lpage>1189</lpage>.<pub-id pub-id-type="pmid">19235886</pub-id></mixed-citation></ref></ref-list></back></article>